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HIV Can Establish Latency by Direct Infection of Resting CD4+ T Cells
Abstract
HIV establishes a latent reservoir in a small pool of resting CD4+ T cells early in the infection of a new host.
This viral reservoir has a very slow rate of decay and it is resistant to anti-retroviral therapy and the immune
surveillance. This reservoir poses a significant obstacle to the eradication of virus in an infected individual. It is
thus of importance to understand how this reservoir is established and what are the requirements for its
establishment. One widely accepted theory suggests that latently infected resting cells arise as activated cells
become infected during the transition to a resting state. Contrary to this model, the work done for this
dissertation supports an alternative model for the establishment of the latent reservoir. In this alternative
model, HIV can establish latency in resting CD4+ T cells by direct infection. Using sensitive kinetic PCR
techniques and careful analysis of HIV DNA intermediates at late time points post- infection in vitro, we
found that HIV can fuse, reverse transcribe and finally integrate directly into resting CD4+ T cells in absence
of cellular activation. The findings presented here suggest that this process can take place even when the
resting cells are exposed to low inoculums of virus. In addition, work in this dissertation indicates that HIV
can integrate directly into both major subsets of resting CD4+ T cells, memory and naïve cells. Therefore,
both memory and naïve resting CD4+ T cells can serve as latent reservoirs for HIV. Finally, the finding that
HIV can integrate in resting cells suggests that gene therapy approaches that target resting CD4+ T cells can
be developed. Altogether, the findings in this dissertation have the potential to influence the focus of future
therapeutic drug approaches for the reduction or elimination of the latent reservoir and suggest that
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ABSTRACT
HIV CAN ESTABLISH LATENCY BY DIRECT INFECTION OF
RESTING CD4+ T CELLS
Luis M. Agosto
Dissertation Supervisor: Una O’Doherty
HIV establishes a latent reservoir in a small pool of resting CD4+ T cells early in the
infection of a new host. This viral reservoir has a very slow rate of decay and it is
resistant to anti-retroviral therapy and the immune surveillance. This reservoir poses a
significant obstacle to the eradication of virus in an infected individual. It is thus of
importance to understand how this reservoir is established and what are the requirements
for its establishment. One widely accepted theory suggests that latently infected resting
cells arise as activated cells become infected during the transition to a resting state.
Contrary to this model, the work done for this dissertation supports an alternative model
for the establishment of the latent reservoir. In this alternative model, HIV can establish
latency in resting CD4+ T cells by direct infection. Using sensitive kinetic PCR
techniques and careful analysis of HIV DNA intermediates at late time points post-
infection in vitro, we found that HIV can fuse, reverse transcribe and finally integrate
directly into resting CD4+ T cells in absence of cellular activation. The findings
presented here suggest that this process can take place even when the resting cells are
exposed to low inoculums of virus.  In addition, work in this dissertation indicates that
HIV can integrate directly into both major subsets of resting CD4+ T cells, memory and
naïve cells. Therefore, both memory and naïve resting CD4+ T cells can serve as latent
vreservoirs for HIV. Finally, the finding that HIV can integrate in resting cells suggests
that gene therapy approaches that target resting CD4+ T cells can be developed.
Altogether, the findings in this dissertation have the potential to influence the focus of
future therapeutic drug approaches for the reduction or elimination of the latent reservoir
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1Chapter 1 - Introduction
Section 1.1 – Introduction to HIV and AIDS
Acquired immunodeficiency syndrome (AIDS) is a chronic disease caused by the
retrovirus human immunodeficiency virus (HIV) and it is characterized by the
progressive decay of the immune system and eventual death of the infected individual. Of
the two types of HIV known, HIV type 1 is responsible for the pandemic that affects
approximately 33 million people worldwide and it is responsible for the death of
approximately 2 million people annually (1). These statistics make AIDS one of the
leading causes of death by a single infectious agent worldwide (2). The virus is typically
transmitted from one individual to another via sexual contact and blood-to-blood contact.
Once the virus crosses mucosal tissue or enters the blood stream, the virus targets cells of
the immune system for replication.
Viral replication starts by attachment of the viral particle to its target cell followed
by fusion into the target cell (3). This process is initiated by binding of the viral envelope,
composed of heterotrimeric gp120 and gp41, to the cellular receptor CD4. Upon binding
to the receptor, conformational changes on gp120 occur that enable the envelope to
interact with a cellular seven-transmembrane co-receptor. Several co-receptors have been
shown to mediate fusion of HIV to target cells in vitro, however the most clinically
relevant co-receptors are CCR5 and CXCR4 (4). The ability of a viral particle to use
either or both co-receptors influences the ability to infect different cell types (5). Upon
interaction with the co-receptor, further conformational changes on the viral envelope
take place that lead to the insertion of gp41 into the cellular membrane, thus mediating
2fusion of the particle to the cell. Although viral fusion has long been considered to take
place at the surface of the cell, recent data suggest that HIV may fuse by an endocytosis-
dependent, but pH-independent, mechanism as well (6). After this fusion step, the viral
core is delivered from the cytoplasm to the nucleus, likely by transport along
microtubules (7). The viral core contains capsid, the genome, reverse transcriptase,
integrase, and the auxiliary protein vpr (7-9). This complex of viral proteins is known as
the reverse transcription complex. During its transport to the nucleus, the reverse
transcription complex undergoes uncoating by a still unknown mechanism (10). During
this process the genome is reverse transcribed (8, 9, 11). However, it appears that reverse
transcription is initiated prior to fusion into the cell (12-15) and completion of reverse
transcription may not be required for integration into the host genome (16). At the late
stage of reverse transcription, the viral protein-nucleic acid complex, now known as the
pre-integration complex, is delivered to the nucleus for integration into the host DNA. At
this stage, the pre-integration complex has lost some of the viral proteins, such as capsid
and nucleocapsid, and it is associated with many cellular proteins that may facilitate
nuclear import and integration site selection (10, 17, 18). The viral integrase protein
finally carries out integration of the viral genome into the cellular DNA (10, 19). Once
integrated, the viral DNA becomes a template for the production of the next generation of
viral particles (19).
HIV can replicate in CD4-expressing cells, such as macrophages and dendritic
cells, but the major targets are CD4+ T cells (19). CD4+ T cells are key players in the
initiation of effective adaptive immune responses against pathogens and are essential for
the maintenance of long lasting immunological memory after the infection has been
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Figure 1.1. Relative comparison of viral load to CD4+ T cell counts throughout the
course of HIV infection.
The gray line represents the relative viral load by viral RNA copies per ml of plasma and
the black line represents the relative CD4+ T cell count per ml of blood. Figure is based
on work by Piatak, et al. (20), Pantaleo, et al. (21).
4controlled (22). Progressive depletion of these cells is associated with viral replication
and leads to ineffective immune responses. After significant depletion of CD4+ T cells
has occurred, the immune system can no longer control infections that are typically
weakly pathogenic in individuals with healthy immune systems. These types of
infections, also known as opportunistic infections, lead to health complications that
eventually cause the death of the patient.
The progression of HIV infection can be divided into 3 stages: a) acute infection,
b) chronic infection, and c) onset of AIDS and opportunistic infections (Figure 1.1 and
(20, 21)). Acute infection is characterized by the appearance of significant levels of viral
RNA in the plasma within the first weeks of primary infection and the corresponding
depletion of CD4+ T cells from the blood and peripheral lymphoid tissues. This depletion
of CD4+ T cells is most clear in gut lymphoid tissue, where the majority of the CD4+ T
cell population resides (23) and where the vast majority of the cells are depleted within
the first weeks of infection (24). Although the cell numbers in the blood recover partially
after acute infection, their numbers slowly but progressively decline during the chronic
stage of infection, which could last years without any apparent symptoms. This
progressive decline in the numbers of CD4+ T cells is thought to result, not only from
viral replication but also from generalized immune activation (25). Because of the
constant exposure to viral antigens, CD4+ T cells are consistently becoming stimulated
thus, providing more targets for viral replication and more targets for CD8+ T cell-
mediated killing (25). Cell activation also drives increased turn over of the cells, reducing
the pools of naïve and central memory cells and potentially increasing the rate of
activation-induced apoptosis (25). Finally, the levels of CD4+ T cells reach a threshold
5level of approximately 200 cells/ml in the blood, which correlates with the onset of
opportunistic infections, a main characteristic of AIDS.
Section 1.2 – Treatment and Reservoirs
With the advent of combination therapy, or highly active anti-retroviral therapy
(HAART) (26, 27), the mortality rate due to AIDS has been reduced in regions where
treatment is accessible (1). Standard HAART consists of 2 nucleoside analogs, to block
reverse transcription, and a non-nucleoside analog. This and similar combinations of
drugs targeting different steps of the viral life cycle are essential for reducing the
selection of treatment resistant variants as in the case in mono-therapy (28). The success
of HAART in keeping viral loads under detectable levels indefinitely, led to the hope that
after long-term treatment, the infection could ultimately be cured. Unfortunately, HIV
integrates its genome into the host DNA and establishes stable cell-associated viral
reservoirs that have very slow decay rates (29-31). Once integrated into the genome of a
resting cell, HIV is resistant to immune surveillance, because HIV gene transcription is
minimally active in these cells (32, 33) and thus, viral antigens are minimally presented
to immune effector cells. In addition, since drug therapy is only effective against
replicating virus, HAART is also ineffective against latent HIV (34, 35). Therefore, even
if the viral load were kept under undetectable levels with prolonged HAART, the viral
load rebounds after interrupting treatment (36, 37). The main characteristic of these
reservoirs is viral persistence for long periods of time (38). Several viral reservoirs that
are sources of the rebounding viremia have been described. These include tissue-resident
macrophages (39, 40), central nervous system-resident microglial cells (41), both of
which can persistently produce virus throughout the life of the cell (days to months)
6without cytopathic effects (42-44), hematopoietic progenitors (45), and latently infected
resting CD4+ T cells (46, 47).
Section 1.3 – Models of Latency
The latent reservoir in resting CD4+ T cells is the best understood of the HIV
reservoirs and it is established during the early stages of infection of a new host (48).
This reservoir could be formed by two potential mechanisms: a) infection of activated
cells in the process of reverting to memory cells (Figure 1.2A)(30) and b) as proposed by
our group, direct infection of resting cells (Figure 1.2B). Initial work evaluating the
susceptibility of resting CD4+ T cells to HIV infection suggested, unlike their activated
counterparts, that they were not permissive to HIV infection because: a) no virus
production was detected in the supernatants of inoculated resting cells (49-51), b)
integration was not detected (46, 52), and c) reverse transcription was inefficient (53-55).
However, infected resting cells are found in HIV-infected individuals undergoing
HAART (31, 34, 56), which carry both unintegrated and integrated forms of HIV DNA
(46, 47, 57, 58). Two types of latency could explain these seemingly paradoxical
observations: pre-integration and post-integration latency. Because HIV is thought not to
integrate into resting cells, it has been proposed that unintegrated reverse transcripts are
preserved in these cells until the cells are stimulated, thus establishing pre-integration
latency (59). This type of latency was supported by in vitro experiments showing that
viral production from CD4+ T cells can be restored upon stimulation of the cells at
various time points post-infection (53, 54, 60). However, the stability of this form of
latency has been questioned (61).  Work by Pierson, et al. indicates that pre-integration
latency is unstable with a half-life of ~1 day. To establish the more stable post-integration
7       
Figure 1.2. Models of HIV latency in resting CD4+ T cells.
(A) Model of HIV latency where latently infected cells form by infection of activated
cells as they return to a resting state to become memory cells. Only cells in a “semi-
activated” but still permissive state during their return to a resting state can become
latently infected because fully activated cells succumb to cytopathic effects during viral
replication (62). (B) Model of HIV latency where HIV can integrate directly into resting
CD4+ T cells without any cellular activation and without any infectious virus production.
8Figure 1.3. Diagram of nested Alu-PCR for the detection of integrated HIV DNA
and a hypothetical profile of kinetic PCR amplification.
(A) Nested Alu-PCR as described by O’Doherty, et al. (63) involves a pre-amplification
step and a kinetic secondary amplication. In the pre-amplification step, the region
between gag, in the HIV genome (black region), and the nearest Alu sequence in the
human genome (gray region) is amplified by end-point PCR. Half of the PCR product of
this reaction is then used to amplify those amplicons that contain HIV sequences by
kinetic PCR. The primers used in the kinetic reaction recognize the R-U5 region of the
HIV long terminal repeat region. (B) The amplification profile of this reaction from an
unknown sample (dashed line) is then compared to the profile of a serially diluted
integration standard (solid lines) that contains a known number of copies of integrated
HIV DNA (numbers above curves) to estimate the number of integration events.
9latency, it was proposed that the resting cells must have undergone cellular activation
prior to becoming resting cells and must had been exposed to HIV at some point while
the cell was active. Given that productive HIV infection commonly results in the death of
the infected cell, it was proposed that the cell must have become infected during the
process of returning to a resting state, after performing its immunological functions (30).
This hypothesis is supported by evidence from in vivo studies, indicating that, in most
infected individuals, the majority of the resting cells carrying integrated virus have a
memory phenotype (35, 64). However, this hypothesis must be reconciled with evidence
from other in vivo studies showing significant infection of resting cells, especially during
acute infection, and infection of naïve cells, which are considered to be more quiescent
(40, 65-69). These cells are considered to be in a more quiescent state because they
appear to be in G0 stage of the cell cycle based on RNA expression, while memory cells
appear to be in the G1a stage of the cell cycle (70). The finding that naïve cells appear to
be infected in vivo is difficult to reconcile with the theory that HIV cannot directly
integrate into resting cells. To explain these observations, it has been proposed that naïve
cell infection could represent pre-integration latency (30) or that infected naïve cells had
reverted from a memory phenotype (71).
An alternative hypothesis to explain the formation of the pool of post-integration-
latently infected resting cells, including naïve cells, is that an activation step may not be
required for integration in resting cells. With the development of improved methods for
the detection of HIV DNA intermediates, such as nested kinetic Alu-PCR (Figure 1.3 and
(63)), and careful examination of HIV DNA intermediates at late time points post-
infection, our laboratory (72, 73) has provided evidence that HIV can integrate directly
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into resting cells based on in vitro experiments. Later work done by others (74, 75) has
provided evidence supporting our results. These findings support the hypothesis that HIV
can establish latency in resting CD4+ T cells by direct integration in the absence of
activating stimuli. However, the kinetics of infection in resting cells seem to proceed at a
slower pace compared to infection in activated cells. This difference in infection kinetics
suggests that resting cells may have different requirements for infection compared to
activated cells.
Understanding what conditions or factors influence the pace of the early steps of
HIV infection could reveal the existence of factors that may be found in activated but not
in resting cells and that may be necessary for increased efficiency of individual early
steps of infection. Alternatively, there could also be factors present in resting cells that
may be delaying the progress of infection. Therefore, determining which mechanism HIV
utilizes primarily for establishing its reservoir in resting cells could influence the focus of
future treatments for either reducing the formation of the reservoir or eliminating it. The
finding that HIV can integrate directly into resting cells also opens the doors for the
development of cutting-edge strategies for the treatment or prevention of HIV infection
such as gene therapy.
Section 1.4 – Gene Therapy and Resting CD4+ T Cells
Gene therapy is becoming an important strategy for the treatment of many
diseases, such as immunological disorders, certain cancers, and has the potential to be
used effectively against infectious diseases (76-78). This has encouraged a significant
amount of research devoted to the development of effective anti-HIV gene therapy (79).
For gene therapy to be effective and feasible for the treatment of HIV or any other
11
                
Figure 1.4. Outline of lentiviral vector production.
A plasmid encoding the lentiviral vector carrying the gene of interest (Gene X) is
transfected into 293T cells along with a plasmid encoding the essential genes required for
viral assembly and production that are missing in the lentiviral vector construct. The
method shown in this figure is similar to the method used for the production of the
lentiviral vector VRX494 (80). This vector was used for experiments described later in
this dissertation. The viral particles produced from the transfected cells contain the
normal structural features of a lentiviral particle and carry the vector expressing the gene
of interest. Lentiviral particles carry 2 copies of the vector, only 1 copy is shown for
simplicity. To increase or narrow the range of cells that can be targeted by the vector,
envelope proteins from other viruses can be used to pseudotype the particles. These
include vesicular stomatitis virus g-glycoprotein (81-83), influenza HA (84), measles
virus F and H proteins (85), and amphotropic-murine leukemia virus envelope (86, 87).
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disorder, an efficient and safe method for the delivery of the desired therapeutic gene
must be developed. A method that has been favored by many researchers is the delivery
of genes of interest using HIV-based lentiviral vectors (Figure 1.4).
 In these vectors, the natural HIV genes are replaced with a therapeutic gene of
interest, but still preserve the features that are essential for efficient reverse transcription
and integration into the host genome. This allows the vector to be stably expressed in the
target cell and prevents the vector from being lost as a result of target cell division.
Lentiviral vectors are also very flexible in the viral envelopes they can carry. By a
method called pseudotyping (88), lentiviral vectors can be assembled using foreign
envelope proteins, broadening the range of cells that can be targeted or giving the vector
sufficient precision to deliver genes to a particular cellular target. Lentiviral vectors also
have a different integration site selection pattern compared to other retroviral-based
vectors. While gamma-retroviruses, another common gene therapy vector type, favor
integration near the 5’ ends of transcription units (89), lentiviruses favor integration
within active transcription units with no apparent favoring for the 5’ ends of genes (90,
91). This characteristic of the lentiviral vectors reduces the risk of affecting proto-
oncogenes or tumor suppressor genes, as was the case in a gamma-retrovirus-based
vector trial (92, 93). An additional advantage of lentiviral-based vectors is their ability to
integrate into non-dividing cells (82, 83).
For the treatment of HIV, resting CD4+ T cells and hematopoietic stem cells are
desirable targets for gene therapy. In the case of resting CD4+ T cells, these are one of
the most important HIV reservoirs in vivo, and in the case of hematopoeitic stem cells,
they are the source of all blood cell lineages including CD4+ T cells (22). Thus,
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genetically modifying these cells could protect them from HIV infection. However,
resting CD4+ T cells (46, 52-55, 94-96), similar to G0 hematopoietic stem cells (94),
have long been thought to resist lentiviral-mediated transduction. To overcome this
apparent obstacle, current gene therapy protocols include an activation step of the target
cells before transduction (79). However, a potential disadvantage of activating cells prior
to transduction is that it may alter the natural physiologies of the target cells (97) and
thus, could adversely affect the effectiveness of the genetic therapy. Further investigation
on the biology of resting cell infection by HIV may provide clues on how to overcome
the obstacles preventing the efficient transduction of resting CD4+ T cells with lentiviral
vectors. A better understanding of the requirements of HIV infection in this cell type is,
therefore, of great importance in order to improve the efficiency and feasibility of future
gene therapy approaches.
Section 1.5 – Dissertation Research
This dissertation is aimed at providing further insight into the biology of HIV
infection of resting CD4 + T cells. We developed an improved Alu-PCR method for the
detection of HIV integration by incorporating a polyclonal integration standard and
repetitive sampling. This improved assay allows the detection of 1 integration event per
10,000 cells (Chapter 2). With the use of this method, we found that HIV can integrate
directly into resting CD4+ T cells even when the virus is delivered at low inoculum,
though still to a lower extent compared to fully activated CD4+ T cells. This suggests
that a single infectious viral particle is capable of integrating into a resting cell and if
cellular restriction factors exist, they seem to only delay but not prevent the final outcome
of HIV integration. This evidence supports a model where post-integration latency is
14
established directly in resting cells. However, this study was conducted in a
heterogeneous population of resting cells containing both resting memory and resting
naïve CD4+ T cells.
Naïve CD4+ T cells are considered to be the most quiescent of the two cell
subsets and thus potentially more resistant to HIV infection. A potential difference in
susceptibility between these two cell subsets was previously suggested (98, 99).
However, because these studies were conducted in stimulated cells, it remained unclear if
HIV infection differed between resting memory cells and resting naïve cells. To address
this question, we compared the relative efficiency of the early steps of HIV replication in
resting memory to resting naïve CD4+ T cells (Chapter 3). We found that both subsets
were susceptible to CXCR4-tropic HIV infection but resting naïve cells were resistant to
CCR5-tropic HIV infection because of inefficient viral fusion. This finding is consistent
with lower expression of CCR5 among resting naïve CD4+ T cells compared to memory
CD4+ T cells, suggesting that receptor availability and viral entry are the limiting factors
restricting infection of naïve CD4+ T cells. Thus, the activation status of the cell does not
appear to play a significant role in determining the susceptibility of a resting cell to HIV
infection. In turn, our results indicate that HIV can integrate directly into resting naïve
cells when given the appropriate envelope to enter the cell.
Since HIV can directly fuse, reverse transcribe and integrate into resting CD4+ T
cells, we investigated whether this was also the case in lentivirus-based gene therapy
(Chapter 4). Using a lentiviral vector similar to the one used for a clinical trial of AIDS
patients (100), we explored what the requirements are for lentiviral vector integration into
resting cells. We found that VSV-G, a common envelope used for pseudotyping lentiviral
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vectors (81-83), did not allow fusion of the vector to resting cells. However, if the vector
is pseudotyped with native HIV envelope, the ability of the vector to integrate into resting
cells is rescued. In addition, it appears that the incorporation of the HIV auxiliary proteins
Vif, Nef, and Vpr into virions (101-105) are not required for integation into resting cells
since the vector does not carry them but it is still able to integrate in these cells.
The work in this dissertation highlights the importance of understanding resting
cell infection to address important questions in HIV pathogenesis. The findings presented
here provide further support to the theory that HIV can establish latency in resting cells
by direct integration into these cells. However, even though integration takes place in
resting cells, it appears that it takes place with less efficiency than in fully activated cells.
Understanding what factors influence infection kinetics could reveal novel targets for
drug therapy. Furthermore, this dissertation provides evidence that naïve cells can serve
as a reservoir for HIV and that this reservoir can be established by direct infection of the
resting naïve cells. Finally, the present work also suggests that the knowledge on HIV
infection of resting cells can be directly applied to the development of gene therapy
approaches that target resting CD4+ T cells. Our data shows that lentivirus-based vectors
have the ability to directly integrate into resting cells when given the appropriate viral
envelope. Altogether, this dissertation suggests that further work in the area of resting
cell infection will be instrumental in the development of new therapeutic strategies to
treat HIV infection more efficiently.
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Chapter 2 - HIV-1 integrates into resting CD4+ T cells even at low
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Section 2.1 – Abstract
Human Immunodeficiency Virus Type I (HIV-1) establishes a latent reservoir early in
infection that is resistant to the host immune response and treatment with highly active
antiretroviral therapy (HAART). The best understood of these reservoirs forms in resting
CD4+ T cells. While it remains unclear how reservoirs form, a popular model holds that
the virus can only integrate in activated CD4+ T cells. Contrary to this model, our
previous results suggest that HIV-1 can integrate directly into the genomes of resting
CD4+ T cells. However, a limitation of our previous studies was that they were
conducted at high viral inoculum and these conditions may lead to cellular activation or
saturation of restriction factors. In the present study, we tested if our previous findings
were an artifact of high inoculum. To do this, we enhanced the sensitivity of our
integration assay by incorporating a repetitive sampling technique that allowed us to
capture rare integration events that occur near an Alu repeat. The new technique
represents a significant advance as it enabled us to measure integration accurately down
to 1 provirus/well in 15,000 genomes – a 40-fold enhancement over our prior assay.
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Using this assay, we demonstrate that HIV can integrate into resting CD4+ T cells in
vitro even at low viral inoculum. These findings suggest there is no threshold number of
virions required for HIV to integrate into resting CD4+ T cells.
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Section 2.2 – Introduction
Human Immunodeficiency Virus-1 (HIV-1) establishes a latent infection that
effectively evades immune surveillance and drug therapy (1-6). The best characterized
latently infected cells are resting CD4+ T cells. It is thought that latently infected cells
form when HIV DNA integrates into an activated cell just before that cell returns to a
resting state (7). This hypothesis is supported by early findings in vitro (8-13, 14 , 15)
and in HIV infected individuals (16-18). However, this hypothesis must be reconciled
with studies showing that HIV (and SIV) is produced from CD45RA
+
 naïve CD4+ T cells
in HIV infected organ cultures (19) and in HIV (and SIV) infected individuals (20-22).
The fact that HIV is produced from naïve cells suggests that an activation step may not be
required for HIV integration, although it is also possible that all the CD45RA
+
 cells that
are producing HIV are not truly naïve (23) or that naïve cells receive an activating stimuli
that allows productive infection to occur without causing the cell to switch to the
CD45RO isoform.
At odds with the early in vitro findings (15), we recently reported that integration
does occur in resting CD4+ T cells inoculated with HIV in vitro (24). In this study, we
used high viral inoculum conditions in order to obtain a measurable transduction
frequency. To achieve high viral inoculum conditions, we used a technique called
spinoculation which deposits many virions to each resting CD4+ T cell (25). Thus, it was
possible that the observed integration in resting T cells was due to these artificial
conditions. It was possible that the high inoculum conditions may have activated the cells
without inducing upregulation of activation markers. Consistent with this idea, it had
been reported that productive infection of inoculated PBMCs occurs when these cells are
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exposed to high concentrations of gp120 (26), presumbably by inducing cross-linking of
CD4 (27-29). Alternatively, it was possible that depositing many virions per cell could
saturate restriction factors in a manner similar to cross-species saturation of
TRIM5! (30-37). Notably, the saturable nature of HIV-1 restriction in resting CD4+ T
cells has not been directly investigated. To address these possibilities, we set out to test
whether a threshold number of virions are required to bind to resting CD4+ T cells in
order for integration to occur.  In other words, we sought to determine if HIV could
transduce resting CD4+ T cells under low virus inoculum conditions. To approach these
questions, we found it necessary to improve our original integration assay because it
lacked the sensitivity required to detect low levels of provirus (38).
In the present study, we increase the sensitivity of our original integration assay,
which used Alu-gag PCR to distinguish integrated from unintegrated DNA (38). We
demonstrate that an inherent limitation of Alu-gag PCR is variable amplification at low
proviral copy number. As a result, integration is only detectable when HIV inserts close
to an Alu repeat limiting the sensitivity of the Alu-gag PCR. We go on to show that the
sensitivity of our method is enhanced ~40-fold by testing samples repetitively. Sampling
repetitively not only reduces the standard deviation, but, more importantly, it enables us
to capture rare integration events where HIV integrates close to an Alu element. Using the
more sensitive integration assay, based on repetitive sampling, we demonstrate that
integration can occur in resting CD4+ T cells even under low viral inoculum conditions.
These findings suggest that there is no threshold number of virions required for
integration to occur and that the interaction of a single viral particle with a resting CD4+
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T cell and any stimulus that this interaction may cause are sufficient for integration of
HIV.
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Section 2.3 – Results
2.3.1 Generation of a standard curve demonstrates enhanced sensitivity with
repetitive sampling. (Figure 2.1)
To calculate HIV integration events, we needed to compare the level of integration in our
unknown samples to a standard that contained diverse integration sites to accurately
reflect integration in vivo (39). We generated an integration standard cell line (IS) with
diverse integration sites at ~1 integration event per cell (not shown) using a similar
strategy as our previous work (38). The strategy that we used to determine that there was
one integration event per cell and that all the HIV DNA was integrated is detailed in
Supplement S2.1 and in the Materials and Methods (Section 2.5). Our integration assay is
based on Alu-PCR, which uses primers for the repetitive element Alu of the human
genome and for the gag gene of HIV. We then measured the level of Alu-gag signal
generated with the IS and compared it to the signal generated using only the gag primer,
which provides the signal from unintegrated DNA. We reasoned that we could enhance
the sensitivity of our assay by repetitive sampling to capture single integration events on
the rare occasion that HIV integrated near to an Alu site. To test this hypothesis and to
determine the sensitivity of our assay when performed repetitively, we serially diluted
our IS DNA in DNA of uninfected PBMCs and then assayed each dilution 40 times
(Figure 2.1A). We consistently assayed total DNA concentrations equivalent to 1.5x10
4
cells per reaction (IS cells + uninfected PBMC) to maintain a constant number of Alu
sites (see the PCR conditions section of Materials and methods for explanation). When
160 proviruses in 1.5x10
4
 genomes were assayed repetitively, the standard deviation was
small and the Alu-gag and gag-only signals did not overlap. When 80 proviruses per
1.5x10
4
 genomes were assayed, the standard deviation increased, but integration was
30
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Figure 2.1. Repetitive sampling increases the sensitivity of the integration assay.
(A) DNA from the polyclonal IS was diluted into a constant amount of uninfected human
genomic DNA and subjected to our 2-step Alu-PCR. The first PCR reaction used primers
to Alu and gag or only primers to gag. The second PCR reaction used HIV-1 specific
primers to the LTR elements, R and U5. For each dilution sample, Alu-gag and gag-only
(background) amplification was measured 40 times and the provirus number was
determined. At low proviral copy number, integration is detected at a low frequency as
demonstrated by the Alu-gag amplification. For clarity, we did not show the gag-only
signals at the lower dilutions, but instead show the bracketed black lines (  ), which
represent where the gag-only signal (background) was detected at each proviral number.
(B) A log-log relationship exists between the average cycle threshold value and the
provirus number. Given the provirus number in our integration standard, we were able to
determine the relationship between the average cycle threshold (CT) value and the
provirus number. The average cycle threshold is obtained by averaging the cycle numbers
where each PCR amplification curve crosses the y = -2.5. After calculating the average
CT for IS at several provirus counts, a linear regression was performed on the natural
logarithm of the average CT and the natural logarithm of the average provirus count to
obtain the following formula: 
! 
ln n( ) " #9.6999 $ ln Ct( ) + 33.079 . Each point represents
40 measurements performed at each IS concentration and the error bars represent the
standard deviation.
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detectable 100% of the time. When less than 40 proviruses per 1.5x10
4
 genomes were
assayed, only a fraction of the samples gave a positive signal, i.e. several Alu-gag signals
overlapped with the gag-only signal. Nonetheless, a reproducible relationship existed
between the number of proviruses at low copy number and the average of the Alu–gag
signals. With this assay, we could detect down to ~1 provirus per 15,000 genomes 10%
of the time since 4 out of 40 Alu-gag signals were statistically different from the gag-only
signal (p<0.02 by the Student t-test). Thus, the sensitivity of our assay was increased by
about 40-fold since the detection limit of our prior integration assay was about ~40-80
proviruses per reaction.
Finally, we determined how the cycle threshold varied with the number of
proviruses by calculating the average Alu-gag cycle threshold (including the signals that
overlapped with the gag-only signal) and plotting it against the proviral number for IS.
We observed a linear relationship between the natural logarithm of the proviral number
(n) and the natural logarithm of the average cycle threshold (ln):
079.33ln6999.9ln +!= µn  with R2= 0.975 (Figure 2.1B).
2.3.2 Integration is not detected when HIV inserts far from an Alu sequence. (Figure
2.2)
We presumed that the undetectable integration events in Figure 2.1 occurred when
HIV inserted distantly from the nearest Alu. We also presumed that the amplification was
variable due to the variable distance between the provirus and the Alu site. To measure
what is the minimum distance between the site of integration and Alu required for
detection in our system, we compared the efficiency of amplification in four clones that
contained unique integration sites at different distances from Alu. The four clones were
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Figure 2.2. Alu-gag amplification depends on the distance between Alu and
integrated virus.
Alu-gag amplification efficiency was related to the distance between the HIV-1
integration site and the nearest Alu sequence. Alu-gag amplification, and hence
integration, was undetectable when HIV-1 integrated >5000 bp from the nearest Alu site.
(A) Four clones (A, B, C, and D) were derived from polyclonal IS-293. The clones were
generated by culturing IS-293 at ~1 cell/well. For each clone, the distance from the
nearest Alu to gag was determined as described in Materials and methods. (B) Alu-gag
amplification was more efficient when the nearest Alu was close to the integration site
and undetectable when Alu was far from the integration site. DNA from each clone was
subjected to 2-step PCR. Alu-gag and gag-only were measured three times and the
response curves for each clone are shown. In every experiment, a horizontal threshold
line was drawn at y = -2.5. The smaller the distance between HIV-1 gag and Alu, the
more efficient the amplification and the lower the CT (compare A and D). For each clone,
the Alu-gag response curves were compared to the gag-only response curves. When the
distance between HIV-1 gag and Alu was >5000 bp, as in clone D, there was no
difference between the Alu-gag  signal (integration) and the gag-only signal
(background).
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isolated by inoculating 293 cells (IS-293) with VSV-G pseudotyped HIV"env at a low
multiplicity of infection to reduce the chance of individual cells containing multiple
integration sites (in Figure 2.1, CEMss cells were infected while in Figure 2.2, 293 cells
were infected with VSV-G pseudotyped HIV"env). The polyclonal IS-293 cells were
grown in hygromycin and clones were subsequently isolated by limiting dilution. After
28 days in culture, clones were FACS sorted to be uniformly GFP positive. First, we
confirmed that each clone had one copy of HIV DNA per cell by quantitative PCR (data
not shown). Next, for each clone, we employed inverse PCR to clone the HIV integration
site as described (40) and sequenced it. We then aligned the obtained sequence to the
human genome to find the exact location of the integration site. We also determined the
location of the nearest Alu (in the correct orientation, with less than 2 mismatches to our
Alu primer and no mismatches in the 3’ end) by sequence alignment. From these data, we
calculated the distance between the nearest Alu and the HIV integration site (Figure
2.2A).
We found that the smaller the distance between the integration site and the Alu
sequence, the greater the Alu-gag amplification (Figure 2.2B). However, when the
distance between the integration site and the nearest Alu sequence was large, integration
was not detected, in other words, there was no difference between the Alu–gag
amplification and the gag-only primer amplification (Figure 2.2B). We did not detect
integration when HIV inserted > ~5,000 bp from the nearest Alu using a 2.5 minute
extension. Thus, the limit for detecting an Alu-gag amplicon occurs when HIV inserts
between 2,000 and 5,000 bps from the nearest Alu. While longer extension times would
allow amplification of larger Alu-gag amplicons, the overall amplification efficiency was
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not enhanced when we extended the amplification time beyond 2.5 minutes (data not
shown).
2.3.3 Isolation of highly enriched resting CD4+ T cells. (Figure 2.3)
With this improved assay, we tested if HIV-1 could integrate in resting CD4+ T
cells when delivered at low inoculum. Partially purified CD4+ T cells (ppCD4) were
obtained from leukapheresis-enriched PBMC by negative selection rosette and
successfully depleted cells of other lineages (CD8, 16, 19, 36, 56, 66b, TCR#$) yielding
>96% CD4+ T cells (Figure 2.3). However, a significant percentage of these cells
expressed activation markers. The contaminating activated cells were depleted with
magnetic beads and antibodies recognizing markers for T cell activation: HLA-DR,
CD25 and CD69 as described in Materials and methods. After the second purification
step, less than 1% of the cells expressed activation markers (Figure 2.3, compare rCD4
with the fluorescence minus one [FMO] control).
2.3.4 Integration of HIV-1 in CD4+ T cells can be detected at low viral inoculum.
(Figures 2.4 and 2.5)
We previously demonstrated that HIV-1 can integrate in resting CD4+ T cells
under high inoculum conditions. To test if HIV-1 could integrate at low inoculum, we
serially diluted our viral stocks and then inoculated T cells under routine conditions. We
first tested the ability of a VSV-G pseudotyped HIV-1 to integrate into CD4+ T cells
when delivered at low inoculum. ppCD4 (Figure 2.3) were infected with 3-fold serial
dilutions of pNL4-3 VSV-G by standard inoculation for 2hr at 25°C. After inoculation,
samples from high and low inoculation conditions were collected to assess the level of
viral binding by measuring the p24 antigen level with an ELISA (25). The cells were
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Figure 2.3. Purification of resting CD4+ T cells.
PBMC (enriched by leukapheresis) were negatively depleted by RBC rosette using
antibodies against: Glycophorin A, CD8, 16, 19, 36, 56, 66b and TCR#$ to yield >96%
partially purified CD4+ T cells (ppCD4). ppCD4 were then stained with PE-labeled
antibodies with specificities for HLA-DR, CD25 and CD69 in order to deplete activated
cells with anti-PE magnetic beads. Purified resting CD4+ T cells (rCD4) contain less than
1% activated T cells. The gates were placed based on fluorescence-minus-one (FMO)
controls, which were only labeled with anti-CD4. The gates were set conservatively such
that 1% of unstained cells were in the upper quadrants. The above figure represents a
typical purification of resting CD4+ T cells.
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subsequently cultured for 3 days to allow integration to occur in the presence of 1.25 µM
of saquinavir to ensure the infection was limited to a single round. The cells were then
harvested and genomic DNA was purified to measure the total number of cells based on
the number of %-globin genes present (25). We then measured the level of integration in
1.5x10
4
 cells with our improved Alu-PCR assay. As shown in Figure 2.4, integration
occurred under low inoculum conditions and decreased in a dose-dependent manner. In
the same way, the number of reverse transcripts per cell (RU5/cell) decreased in a dose-
dependent manner (Figure 2.4C, D). Similarly, a dose-dependent decrease in reverse
transcription and integration were observed when cells were spinoculated with the same
stock of diluted virus (Supplement S2.2).
In order to determine the validity of the dose response, we plotted the logarithm
of the proviral count and the dilution. The logarithmic conversion of the data revealed a




=0.99). In addition, we detected, on average, less than 1 virion/cell (0.36
virions/ cell) at the end of the inoculation with the most dilute virus (based on p24) and
still detected integration (0.0005 proviruses/cell) (Figure 2.4A, dark bars with asterisks).
This suggests that there is no requirement for a threshold number of virions to be bound
per cell for successful integration. In summary, a dose dependent decrease was obtained
over a 3 log range of viral inoculums, ranging from 800 virions bound per cell down to
~1 virion bound per 3 cells at the end of the inoculation (Figure 2.4 and Supplement
S2.2).
We next tested if a threshold effect exists using purer resting CD4+ T cells
(rCD4) inoculated with wild type HIV-1 (Figure 2.5). It was important to determine if we
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Figure 2.4. Integration of HIV-1 in CD4+ T cells is detected at low viral inoculum.
A dose-dependent decrease in viral integration was observed with serial dilution of the
viral inoculum (A, B). ppCD4 cells were inoculated with three-fold dilutions of
supernatant containing VSV-G pseudotyped pNL4-3. The dark bars indicated by an
asterisk represent the number of virions bound per cell. The top and bottom viral
dilutions correspond to 16 and 0.36 virions/cell respectively based on p24 ELISA (25).
Cells were inoculated by routine inoculation for 2hr at 25°C. A dose-dependent decrease
in RU5 reverse transcripts was also observed with serial dilution of the viral inoculum.
The results are presented in provirus per cell (A), log(3) of provirus per cell (B), RU5 per
cell (C, D) and log(3) RU5 per cell (D). The level of viral integration and reverse
transcripts are shown as log(3) to convert the exponential relationship (A,C) to a linear
relationship (B,D). Error bars represent the standard deviation of 5-51 measurements of
integration and 4-8 measurements of reverse transcripts, respectively, for each virus
dilution depending on proviral number (and sample availability). More repeats were
required to capture integration events at low proviral numbers. The number of
proviruses/cell and RU5/cell are written above each point (B, D).
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Figure 2.5. Integration of wild type HIV-1 in pure resting CD4+ T cells exhibits a
dose-dependent decrease in integration and reverse transcription with each dilution.
A dose-dependent decrease in viral integration (A) and reverse transcription (B) was
observed with serial dilution of the viral inoculum. Resting CD4+ T cells were inoculated
with two-fold dilutions of supernatant containing pNL4-3. Cells were inoculated by
routine inoculation for 2hr at 25°C. After infection, the cells were cultured for 72hr
before measuring integration. The results are presented in log(2) of provirus per cell (A)
and log(2) of RU5 per cell (B). For integration, the error bar at the top dilution represents
the standard error of 5 independent inoculations. Each inoculation at the top dilution was
measured for viral integration 10-12 times depending on sample availability. The error
bars of the lower dilutions represent the standard deviation of 12-42 measurements of
integration for each virus dilution depending on sample availability. In general more
replicates were performed at the lower dilutions. For reverse transcription, the error bar at
the top dilution represents the standard error of 5 independent inoculations. Each
inoculation at the top dilution was measured for reverse transcription 2-6 times depending
on sample availability. The error bars of the lower dilutions represent the standard
deviation of 4-6 measurements of reverse transcription for each virus dilution depending
on sample availability. The number of proviruses/cell and RU5/cell are written above
each point.
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obtained the same results with wildtype HIV-1 since VSV-G-mediated entry differs
significantly from gp120-mediated entry. It was also important to confirm that we
detected integration in the resting fraction of circulating CD4+ T cells as circulating
blood CD4+ T cells (ppCD4) represent a range of activation states. Consistent with the
observations made for pseudotyped HIV-1, a dose-dependent decrease in integration and
reverse transcription occurred in resting CD4+ T cells inoculated with pNL4-3.
Integration could be inhibited by 98% and reverse transcription could be inhibited by
92% in the presence of AZT (added at the top dose). We estimated that ~3 virions were
bound per cell at the top dilution based on p24 ELISA (not shown) which corresponds to
a multiplicity of infection (MOI) of 0.02 as assessed by infection of CEMss-GFP
indicator cells. We also tested the inoculated resting CD4+ T cells for upregulation of
CD69, CD25 and HLA-DR before and 3 days after inoculation and found no detectable
staining at either time point (not shown, but consistent with our previous study (24)). In
our prior report, no activation was detected by three distinct methods. There was no BrdU
incoporation over a 72 hr incubation period, no change in cell cycle by DNA/RNA stain
and no change in activation markers. These studies were performed at higher inoculums
compared to the current study and so we presume that there is less activation in the
current study.
2.3.5 Both resting and intermediately activated CD4+
 
T cells are equally susceptible
to HIV-1 integration at low inoculum conditions. (Figures 2.6 and 2.7)
Circulating CD4+ T cells have a range of activation states. In our prior
publication, we showed that the integration signal we obtained in resting CD4+ T cells
could not be due to rare contaminating strongly activated CD4+ T cells. However, low
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level to intermediately activated CD4+
 
T cells are the predominant contaminants in our
purified resting CD4+
 
T cells. To test if the signal we obtained in our resting CD4+ T
cells could be attributed to contaminating intermediately activated cells we compared the
susceptibility of intermediately activated CD4+
 
T cells relative to resting cells. Resting
and intermediately activated cells were sort purified from PBMC using the FACS Aria
(Figure 2.6). Conservative gates were set around the lineage (FITC) and activation (PE)
double negative population to separate resting cells from the lineage negative and
activation intermediate population. Post-sort analysis of these populations showed that
resting cells were 98% pure and that intermediately activated cells were 94% pure.
Immediately after sorting, both populations of cells were infected with serial dilutions of
pNL4-3. We estimated, by p24 binding assay (25), that approximately 3 virions were
bound per cell (not shown) when the resting and intermediately activated cells were
inoculated with 1:9 dilution of the viral stock, demonstrating that our experiments were
conducted at low inoculum. Reverse transcription and integration were measured at the
peak of reverse transcription and integration, which occurred 24hr after inoculation in
stimulated cells and 48-72hrs after incoculation in resting and intermediately activated
cells.
 Reverse transcription is more efficient in stimulated cells than in resting or
intermediately activated cells (Figure 2.7). Reverse transcription occurred 10 times more
efficiently in the CD3 and CD28 stimulated cells. In this experiment, integration occurred
with similar efficiency in resting, intermediately activated and stimulated cells since
approximately 1 in 5 reverse transcripts integrated. Our data overall however (including
prior work (24)) suggest that integration is slightly more efficient in activated cells as we
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find between 1 in 2 to 1 in 5 reverse transcripts integrate in activated cells and between 1
in 5 and 1 in 13 reverse transcripts integrate in resting CD4+ T cells.
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Figure 2.6. Sorting strategy to obtain highly pure resting and intermediately
activated CD4+ T cells.
Resting and intermediately activated CD4+ T cells were sort-purified from PBMC by
FACS Aria. PBMC were stained with FITC-labeled antibodies against lineage markers
(CD8, CD14, CD16, CD20, CD56) and PE-labeled antibodies against activation markers
(CD25, CD69, HLA-DR)(pre-sort). Gates were set around the double negative and
activation intermediate populations to obtain 98% and 94% pure resting and
intermediately activated CD4+ T cells respectively (post-sort).
45
                                        
Figure 2.7. Both resting and intermediately activated CD4+ T cells have similar
susceptibility to HIV-1 integration.
Resting, intermediately activated and stimulated CD4+ T cells were infected with 3-fold
dilutions of the same pNL4-3 stock, but a different stock of virus than in Figure 2.5. After
infection, the cells were cultured for 48 (resting and intermediately activated) or 24hr
(stimulated) before measuring integration (A) and reverse transcription (B). The level of
reverse transcription was determined using primers that detect the second strand transfer
step (SST/cell). Both resting and intermediately activated cells had similar susceptibility
to HIV-1 integration and reverse transcription while stimulated cells were more
susceptible. Error bars represent the standard deviation of 8-15 measurements of
integration and duplicate measurements of reverse transcription depending on sample
availability. The number of proviruses/cell and SST/cell are written above each point.
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Section 2.4 – Discussion
In the present study, we increase the sensitivity of our original, Alu-gag PCR-
based, HIV integration assay (38) by applying a repetitive sampling technique. Using the
new assay, we demonstrate that HIV integrates into resting CD4+ T cells even under low
viral inoculum conditions. We find a dose-dependent decrease in the level of integration
suggesting that there is no threshold number of virions required to bind to a CD4+ T cell
for integration to occur. A threshold effect seemed likely since high viral inoculums
might activate CD4+ T cells (26, 28) or possibly saturate a restriction factor that might be
present in resting CD4+ T cells.
We used the new, more sensitive integration assay to test if integration can occur
under low inoculum conditions. Integration occurs (albeit at low levels, e.g. ~5 in 10,000
CD4+ T cells, Figure 2.4) even when, on average, less than one virion was bound per T
cell at the end of the inoculation. Similar observations were noted when we inoculated
pure resting CD4+ T cells with wild type HIV-1 (~2 in 10,000 cells, Figure 2.5). It could
be argued that the rare integration events that we detect under low inoculum are due to
integration events in rare activated T cells. However, we demonstrated that
intermediately activated cells, which are the predominant contaminants among our
purified resting cells, have the same susceptibility to integration as resting cells and so
contaminating intermediately activated cells could not account for the signal. In addition,
our prior work (24) demonstrated that rare activated cells contributed less than 5% to the
integration signal detected in resting T cells when infected at high viral inoculum.
Finally, while it can be argued that circulating CD4+ T cells represent a continuum of
activation states, it has been shown that resting CD4+ T cells in blood represent the low
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end of that continuum (41) and so represent the least activated cell that HIV encounters.
Our results suggest that resting and intermediately activated CD4+ T cells - the majority
of circulating CD4+ T cells - , are transduced with similar susceptibility (Figure 2.7).
Our observation that HIV can integrate into resting CD4+ T cells under low virus
inoculum conditions suggests that there is no threshold number of virions required to
bind to a CD4+ T cell for integration to occur. Instead of a threshold, there is a dose-
dependent decrease in the level of integration (as well as viral binding and reverse
transcription when tested). If a threshold number of virions were required for integration
to occur, we would expect that at the threshold dilution there would be a greater decrease
in the level of integration. While our data suggest that there is no threshold effect, our
data are still consistent with the possibility that non-saturable restriction factors, possibly
APOBEC3G/F, play a role during infection of resting cells (42). For example, the
kinetics of reverse transcription and integration are slower in resting T cells than in
activated T cells (13, 14, 42-45) consistent with restriction of an early step in the HIV life
cycle.
Our study demonstrating that HIV integration occurs in resting CD4+
 
T cells is at
odds with many prior studies that suggest an activation step is required (8-10, 12-15, 46-
51). Prior studies show that reverse transcription (13, 14), nuclear import (12, 51) and
integration (10) are blocked in resting T cells. In addition, the fact that integrated HIV
DNA is enriched in memory over naïve CD4+ T cells in HIV infected individuals
suggests that a prior activation step allowed integration to occur (16-18). Thus, in the
current study we tested if HIV integration into resting CD4+ T cells was an artifact of
spinoculation or high inoculum. To the contrary, we establish that integration still occurs
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in resting CD4+ T cells in the absence of spinoculation and under low inoculum
conditions.
The discrepancy between our results and the literature may be explained by
considering two issues: delayed kinetics and assay sensitivity. The early studies that
demonstrate a block in HIV reverse transcription (13, 14), nuclear import (12, 51) and
integration (10) in resting CD4+ T cells were all performed within 24 hrs of inoculation,
but the kinetics are delayed in resting CD4+ T cells and viral intermediates are detected
more easily after 2-3 days of culture (42-45). In addition, the prior integration assays
were probably not sufficiently sensitive to detect integration under routine inoculation
conditions. For example, we would not be able to detect integration in any of the samples
inoculated under routine conditions from Figure 2.5 using our previous standard
integration assay (38). The infection frequency in resting CD4+ T cells in our hands (24,
43) and others (reviewed by (15)) is lower than in fully activated T cells such as the
CEMss cell line. Thus, it would be possible to detect integration in fully activated T cells,
but not in resting T cells.
Notably, our study is in agreement with in vivo studies showing that naïve CD4+
T cells are productively infected in vivo (20, 52) and in lymphoid organ cultures (19). In
addition, the predominant infection of “apparently resting” memory CD4+ T cells during
acute SIV infection also argues for a role of direct infection of resting CD4+ T cells (53,
54). Recently, a second study also reported that integration occurs in resting CD4+ T
cells (55) albeit at lower levels. In our study, the fraction of reverse transcripts that
integrate in resting CD4+ T cells vary from about 1 in 5 to about 1 in 10, which is higher
than the fraction reported by Vatakis et al. The difference between our findings and those
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reported by Vatakis et al., may be related to differences in viral DNA stability. Although
we and Vatakis et al. reported that viral DNA can be stable in resting T cells (43, 55), we
have found the stability of viral DNA to be variable, depending on the blood donor, day
of donation and virus used (unpublished observations). In addition, the discrepancy in the
results may also be related to slight differences in the assays for integration that were
used. Nonetheless, the two studies are similar in two important ways. One, both studies
found that integration occurs in resting CD4+ T cells. Two, both studies found that the
proportion of reverse transcripts that integrate in resting and activated T cells are
comparable or only slightly less efficient in resting CD4+ T cells.
Our original Alu-gag PCR-based HIV integration assay had an inherent limitation:
it lacked the ability to detect all integration events due to the fact that exponential
amplification cannot occur when HIV integrates far from an Alu repeat. We overcame
this limitation by applying a repetitive sampling technique in combination with a proper
integration standard. By repetitively sampling an integration standard we control for
undetectable integration events and variable amplification efficiency. In addition, by
repetitively sampling our unknowns, we enhance our ability to capture rare integration
events. From Figure 2.1A, we estimate that we detect a single provirus in 15,000
genomes approximately 10% of the time (i.e. 4 out of 40 Alu–gag replicates are above the
gag-only signal when we assay on average ~1 provirus per well repetitively). This is a
reasonable result since HIV will only occasionally insert near the Alu sequence (55, 56).
We estimate that repetitive sampling enhances the sensitivity of our assay ~40-fold since
we can detect 40-80 proviruses per well in 100% of the wells (with 15,000 cells per well)
without repetitive sampling and 1 provirus per well with repetitive sampling (Figure
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2.1A). This represents a significant advance over prior techniques (57): linker ligation
PCR (58), Alu PCR (18, 38, 39, 59-63) and inverse PCR (16, 17), which are similar
conceptually and have the same inherent limitation – that only a fraction of integration
events should be detectable due to variable amplicon size. This study is the first to show
how genomic anchor based integration assays perform at low proviral copy with multiple
repeats. Some studies, including our own (38), claimed high sensitivities without showing
repetitive sampling at low copy number. For example, in our prior study (38), we
overestimated the sensitivity of our assay by not recognizing the importance of multiple
repeats at low copy number (and by not diluting our standard in a background of genomic
DNA). Our current study demonstrates that multiple repeats are absolutely necessary at
low proviral numbers to determine the true sensitivity of an integration assay.
The evidence presented here suggests that there is no threshold number of bound
virions required for HIV integration to occur in CD4+ T cells. Thus, a single viral particle
can interact with a resting CD4+ T cell and result in integration. In other words, the direct
interaction of virus with a resting CD4+ T cell may be sufficient for latent infection to
occur. We propose that repetitive sampling as exploited in our new method to measure
HIV integration may provide a step toward measuring integration in patient samples more
accurately. We are currently applying this technique to patient samples in an attempt to
measure more accurately the relative susceptibility of different cell types.
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Section 2.5 – Materials and Methods
2.5.1 Cell lines, plasmids, and viruses.  The CD4+ T-lymphoblastoid cell line CEM-ss
was maintained at 1-5x10
5
 cells per ml. The culture medium used was RPMI 1640
supplemented with 10% heat-inactivated fetal bovine serum, 25 mM HEPES, with 100
µg/ml penicillin-streptomycin (Invitrogen Life Technologies). VSVg pseudotyped (64,
65) virions were collected 24 hours after Ca3(PO4)2 transfection of 293T cells with
pVSVg (pHIT) (66) and pNL4-3"env/GFP/HygR. The reporter virus was derived from
pNL4-3, an X4-tropic molecular clone of HIV (67). The nef open reading frame (orf) was
replaced with a GFP and hygromycin cassette which contained an internal ribosome entry
site between the two orfs. The transfection supernatants were treated with 30 µg/ml of
DNase I (Roche) and 10 mM MgCl2 at 37°C, 1 hr prior to collection. For the infections at
low inoculum, pNL4-3 and pNL4-3 VSV-G were used from 293T cell Ca3(PO4)2
transfection supernatant.
2.5.2 Preparation of the Integration Standard (IS) cell line. CEM-ss cells were
infected with pseudotyped virions (described above) by spinoculation. Briefly, 2x10
7
CEM-ss cells were mixed with 1ml of viral stock (VSVg pseudotyped pNL4-
3"env/GFP/HygR containing 1 µg/ml p24 Gag protein) and placed into one well of a flat-
bottom six-well tissue culture plate. The plates were sealed in plastic bags and
centrifuged in microplate carriers at 1,200xg for 2 hours at 25°C. Cells were collected
and washed once with 50 ml of ice-cold culture medium (RPMI1640 with 10% heat-
inactivated fetal calf serum, 10 mM HEPES, 1% penicillin-streptomycin (Gibco)).
Infected cells were cultured for 2 days and then weaned into 800 µg/ml of hygromycin.
The acutely infected cells contained unintegrated HIV-1 DNA and integrated proviral
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DNA. With every cell division, the level of unintegrated DNA per cell decreased while
the integrated proviral DNA replicated with cellular DNA. After 28 days in culture, the
level of unintegrated DNA became undetectable by Southern blot as demonstrated in our
previous work (38) and the GFP positive transduced cells were selected by FACS sorting.
2.5.3 Preparation of clones with unique HIV integration sites. 293 cells were infected
with VSVg pseudotyped reporter virus pNL4-3"env/GFP/HygR at a low multiplicity of
infection to minimize the chance of multiple transductions within one cell. The 293 cells
were grown for 2 days and then weaned into hygromycin at 800 µg/ml. After hygromycin
selection and expansion, the transduced 293T cells were sorted for expression of GFP.
Clonal populations with unique HIV integrations sites were prepared by culturing cells at
<1 cell/well. Hygromycin was added to the wells after single cell cloning. Clones which
grew in hygromycin were again sorted for expression of GFP. After sorting the GFP
positive cells, we measured the level of HIV DNA per cell using quantitative PCR and
found ~1 copy of HIV per cell consistent with one transduction event per cell.
2.5.4 Identification of unique integration sites within clonal populations. Inverse PCR
was used to clone the integration sites as described (40). Briefly DNA was prepared and
cleaved by Pst1, which cuts genomic DNA frequently, but cleaves pNL4-
3"env/GFP/HygR once at position 1419 (HXB2R coordinates). Digested DNA was then
ligated under dilute conditions to favor intramolecular ligation. Outwardly directed
primers to LTR and gag are designed to exponentially amplify circular DNA. Thus, host
genomic DNA adjacent to the HIV-1 insertion site was amplified along with the 5’end of
the HIV genome. The amplified DNA was cloned and sequenced after a nested reaction
again with outward primers. The genomic insertion site was determined by aligning the
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sequence with the human genome sequence. The nearest Alu sequence that matched the
Alu primer with less than 2 base pair mismatches was located.
2.5.5 PCR conditions to measure proviral number. Two step PCR amplification was
performed as described (38) with some modifications. Briefly, the first amplification was
performed on dilutions of the IS cells as well as samples from infected CD4+ T cells.
The sequence of the first step amplification primers were:  genomic Alu forward 5’ GCC
TCC CAA ACT GCT GGG ATT ACA G-3’ and HIV gag reverse 5’ GTT CCT GCT
ATG TCA CTT CC-3’. The gag primer is different from the previously described primer
(38). It provides a better consensus sequence than the original primer, based on Los
Alamos HIV Sequence Database, and provides more efficient Alu-gag amplification.
DNA from the Integration Standard cell line (IS) was diluted in uninfected peripheral
blood mononuclear cells (PBMC) DNA at 2 µg/ml to keep the number of Alu sites per
reaction constant. We kept the number of Alu sites constant because the first-step PCR
amplification efficiency increased with decreasing number of Alu sites. If we diluted the
IS DNA in buffer our assay would inaccurately appear to be more sensitive. By diluting
IS DNA in uninfected PBMC DNA, we mimic the conditions of low infection frequency.
For similar reasons, we cannot simply add more cellular DNA to enhance the sensitivity
of our assay since the sensitivity decreased as the number of cells per sample increased.
In other words, increased numbers of Alu sites decreased the amplification efficiency. We
also reasoned that keeping the number of genomes low minimizes PCR inhibition, which
occurred more frequently at higher concentrations of genomes.
Reactions were carried out in a volume of 50 µl containing: 10 mM Tris-HCl, pH
8.3; 3 mM MgCl2; 1 mM mixed dNTPs; 50mM KCl; 100 nM Alu forward primer; 600
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nM gag reverse primer; and 0.05 units of Platinum Taq DNA polymerase (Invitrogen
Life Technologies). The thermal cycler (DNA Engine Opticon, MJResearch) was
programmed to perform a two-minute hot start at 94ºC, followed by 20 cycles:
denaturation at 93ºC for 15s, annealing at 50ºC for 15s and extension at 70ºC for 2.5
minutes. The Alu primer binds only to cellular genomic DNA, not to unintegrated HIV
DNA; the gag primer binds to one strand of HIV DNA. When both Alu and gag primers
are used in the amplification, the original template strands and every copy are duplicated
in each round, so amplification becomes exponential. Linear, one-strand amplification
(i.e. primer extension) was also monitored by performing the first amplification PCR with
the gag primer alone. When only the gag primer is used, only one strand of the original
template DNA is copied so amplification is linear. We used the gag-only primer
amplification reaction as a control because it provides the signal expected from
unintegrated HIV DNA. While increased extension times increases the ability of Taq
polymerase to make longer amplicons, the overall amplification efficiency was maximal
at 2.5 minutes of extension.
The second round real-time quantitative PCR was performed using 25 µl of the
material from the first amplification. These were run with an HIV-1 copy number
standard. The sequences of the primers were: LTR (R) forward, 5'-GCC TCA ATA AAG
CTT GCC TTG A-3’; LTR (U5) reverse, 5'-TCC ACA CTG ACT AAA AGG GTC
TGA-3’. The LTR molecular beacon probe, labeled at its 5' terminus with the reporter
fluorophore 6-carboxyfluorescein (FAM) and at its 3' terminus with the quencher 4-(4'-
dimethylamino-phenylazo)-benzene (DABCYL), had the following sequence: 5’-FAM-
GCG AGT GCC CGT CTG TTG TGT GAC TCT GGT AAC TAG CTC GC-DABCYL-
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3'. Reactions were carried out in a volume of 50 !l containing: 10 mM Tris-HCl, pH 8.3;
75 mM KCl; 5.5 mM MgCl2; 500 nM carboxy-X-rhodamine (ROX, Molecular Probes) as
a passive reference; 1.2 mM freshly added dNTPs, 250 nM LTR forward and reverse
primers; 200 nM molecular beacon probe; and 0.025 units of Platinum Taq DNA
polymerase. The reactions were performed on a DNA Engine Opticon (MJResearch)
instrument running Opticon Monitor v1.1 software with the following thermal program: 2
min hot start at 95ºC, 4 cycles of denaturation at 95ºC for 15 sec, annealing at 50ºC for 15
sec, and extension at 72ºC for 1 min followed by 44 cycles of denaturation for 15 sec,
annealing at 50ºC for 15 sec, plate read, and lastly extension at 72ºC for 1 min.
To express integration as a ratio of proviruses per target cell, a kinetic PCR assay
for %-globin DNA was used as described (25). A standard curve is made using purified
DNA from PBMC (Qiagen). The quantity of DNA is determined by OD260/280. The
number of genomes is calculated given that ~3.18x10
9
 bp are present per genome. Minus
strand strong stop DNA (RU5/cell) and the level of DNA that has completed the second
strand transfer step of reverse transcription (SST/cell) were measured as previously
described (24, 38).
2.5.6 Repetitive sampling to measure integration at low proviral copy number.
Alu–gag PCR and gag-only PCR were performed repetitively on 25 µl aliquots of DNA
at 2 µg/ml from the IS line and samples from infected CD4+ T cells.  Then HIV-1
specific kinetic PCR is performed on 25 µl aliquot of the first reaction. After the kinetic
PCR reaction, the cycle thresholds (Ct) for each well are determined, i.e. the cycle value
where the accumulating fluorescence (from fluorescently labeled amplicons) crosses a
specified fluorescent threshold value. In all of the experiments described here, the
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fluorescent threshold value was set at -2.5 for data analysis.  The cycle threshold values
from each concentration of IS and for each sample were then averaged. The average
cycle thresholds from the IS with known proviral count were then used to determine the
relationship between the average cycle threshold and the proviral count (Figure 2.1B).
The proviral number from samples was then calculated by inputting the average cycle
threshold into the equation described in Figure 2.1B.
2.5.7 Purification of resting and intermediately activated CD4+ T cells. For the
studies testing if a threshold number of virions is required for integration, CD4+ T cells
were isolated by negative selection from leukapheresis-enriched PBMC by rosette
(RosetteSep™ kit, StemCell Technologies, Inc.) as recommended by the manufacturer.
Briefly, leukapheresis-enriched PBMC were labeled with antibodies recognizing
Glycophorin A, CD8, CD16, CD19, CD36, CD56, CD66b and TCR#$. A secondary anti-
mouse antibody was added to cross-link labeled PBMC to labeled red blood cells.
Following these labeling steps, the cells were applied to a Ficoll-Paque® (GE Healthcare)
density gradient to remove the cross-linked cell complexes. Resting CD4+ T cells were
then isolated by negative selection with saturating concentrations of PE-labeled
antibodies specific for HLA-DR, CD25, and CD69 (BD Pharmingen™) and anti-PE
magnetic beads (Miltenyi Biotec) as recommended by the manufacturers. After
purification, the cells were cultured overnight in RPMI 1640 culture medium
supplemented with 10% heat inactivated human serum and 1% penicillin-streptomycin
(Gibco).
For the studies comparing the susceptibility of resting and intermediately
activated CD4+ T cells, the cells were sort purified as described (24) but using a FACS
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Aria instrument (BD Biosciences). Briefly, PBMC were isolated from whole blood by
Ficoll-Paque® (GE Healthcare) density gradient. Cells were subsequently labeled with
saturating amounts of FITC-labeled antibodies recognizing lineage markers (CD8, CD14,
CD16, CD20, CD56) and PE-labeled antibodies recognizing activation markers (CD25,
CD69, HLA-DR). The double negative population, corresponding to resting cells, and the
cells expressing intermediate levels of activation markers were selected. Immediately
after sorting the cells were washed once with PBS containing 10% human serum and
resuspended in the appropriate viral supernatant for immediate infection.
2.5.8 Flow cytometry. To determine the level of purity and activation, the cells were
stained in FACS buffer (PBS with 1%BSA and 2mM EDTA) with 10% human serum
and mouse IgG to block non-specific binding, and antibodies recognizing CD3, CD4,
HLA-DR, CD25 and CD69 (BD Pharmingen™). The labeled cells were then screened by
flow cytometry with a FACScalibur instrument (BD Biosciences). The results were later
analyzed with FlowJo software (Treestar). Dot plot gates were set based on an unlabeled
control, single positive controls, and fluorescence minus one controls (FMO) missing one
of the labels. We set our quadrants so that 0.5 – 1% of the events in the unstained sample
gave a positive signal in order to detect low levels of staining.
2.5.9 Stimulation of CD4+ T cells. A portion of the sort-purified cells were selected to
be stimulated prior to infection. Cells were cultured for 72hr in the presence of
CD3/CD28 beads at 3 beads per cell, and 10U/ml of recombinant human IL-2. After
incubation, the beads were removed with a magnet, the cells were washed once with PBS
containing 10% human serum and resuspended in the appropriate viral supernatant.
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2.5.10 Inoculation of primary CD4+ T cells. Purified CD4+ T cells were resuspended
at 1x10
7
 cells/ml in 100 µl of serially diluted viral supernatants. Cells were then
inoculated at 1xg or spinoculated at 1,200xg (25) for 2-3hr at 25°C. Following
inoculation, the cells were washed twice with PBS containing 10% human serum and
cultured in RPMI 1640 culture medium supplemented with 10% human serum, 1%
penicillin-streptomycin (Gibco), and 1.25 µM saquinavir (Roche US Pharmaceuticals) for
24, 48 or 72hr. Selected samples were treated with 100 µg/ml zidovudine (AZT) (NIH
AIDS Reagents Program) to inhibit reverse transcription as a negative control.
2.5.11 Assessment of viral binding. Viral binding was assessed by measuring the level
of p24
Gag
 associated with the samples collected immediately after inoculation as
previously described (25). p24
Gag
 levels were measured by p24-specific enzyme-linked
immunosorbent assay (ELISA; Coulter Corporation, Miami, FL) with little cross-
reactivity to other viral proteins. Binding was subsequently calculated based on the
estimation that 15,800 virions are present per 1 pg of p24 (25, 68). This method provides
a good estimate of viral binding, although it may overestimate the number of infectious
virions bound per cell due to the presence of virus-like particles without genomes or
inactive virions. The limit of sensitivity of our p24 assay is 8pg/ml and so to detect viral
binding at our lowest inoculum (~1 virion per 3 cells), 400,000 cells/ml would be
required, but 1x10
6
 cells/ml were generally used at the lowest inoculum to ensure that the
signal fell in the range of detection.
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Section 3.1 – Abstract
Resting CD4+ T cells restrict HIV infection at or before reverse transcription resulting in
slower kinetics of reverse transcription. In a previous study, we showed that, despite this
restriction at reverse transcription, HIV integration occurs in resting CD4+ T cells, albeit
with slower kinetics. In that study, the resting T cells were a mixture of memory and
naïve cells. Here we asked whether the more quiescent naïve cell subset could be directly
infected by HIV; if so, whether the level of integration in naïve cells was comparable to
that in memory cells. We found that HIV integrates in the naïve subset of resting CD4+ T
cells without prior activation of the cells. The level of integration (provirus/cell) in naïve
cells was lower than that in memory cells. This difference between naïve and memory
cells was observed whether we inoculated the cells with R5- or X4-HIV and could not be
explained solely by differences in co-receptor expression. The presence of endogenous
dendritic cells did not change the number of proviruses/cell in memory or naïve cells and
deoxynucleoside pools were equally limiting. Our results instead indicate the existence of
a novel restriction point in naïve T cells at viral fusion that results in reduced levels of
fusion to naïve CD4+ T cells. We conclude that HIV can integrate into both naïve and
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memory cells directly. Our data further supports our hypothesis that integrated proviral
infection of resting T cells can be established without T cell activation.
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Section 3.2 – Introduction
Resting CD4+ T cells are the major, best understood, reservoir of latent HIV
infection, and are a significant barrier to cure because, upon stimulation of the resting
cells, they are a source of viremia when antiretroviral therapy is interrupted (1, 2). At the
same time, resting CD4+ T cells are considered to be relatively resistant to HIV infection
in vitro (3-7); thus, it is unclear how latent proviruses are established in these cells. The
apparent resistance of resting CD4+ T cells to HIV infection in vitro led to the prevailing
belief that an activation step is required in order for HIV to integrate into resting cells and
therefore that an activation step is required in order for proviruses, when not defective, to
establish latency (1, 2).
Resting CD4+ T cells can be subdivided phenotypically into naïve and memory
subsets as defined by the expression of multiple surface markers, including CD45RA and
CD62L (8, 9). Memory resting CD4+ T cells differ from naïve resting CD4+ T cells in
that they have a lower threshold for activation (9-13). In addition, a subset of memory
resting CD4+ T cells express higher levels of the HIV-1 co-receptor CCR5 than naïve
resting CD4+ T cells while naïve cells express slightly higher levels of CXCR4 than
memory cells (14-16). These differences between these two CD4+ T cell subsets may
have important implications for HIV pathogenesis (17).
Memory cells comprise a greater portion of latent proviral infection than naïve
cells (18) as memory cells contain higher levels of total HIV DNA (19, 20) and integrated
HIV DNA (21, 22) than naïve resting cells in vivo. It is unclear why memory cells are
more infected than naïve cells. One favored explanation is that memory cells are infected
while in an activated state before returning to quiescence (1, 2), and that the occasional
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naïve cells infected with HIV in vivo are cells that have reverted from a memory
phenotype (9). This explanation has been favored because it was thought until recently
that HIV could not directly infect cells in the G0/G1a stage of the cell cycle (1, 2, 23).
Alternatively, direct infection of resting CD4+ T cells may occur, which may lead
to latent infection when the provirus is not defective. Recent data suggests this is possible
given that HIV can directly infect and integrate into G0/G1a CD4+ T cells, albeit with
slower kinetics (24-27). Furthermore, massive infection of “apparently” resting memory
CD4+ T cells is detected during acute infection (28-30) suggesting that direct infection of
resting cells may occur in vivo. In addition, infected naïve T cell subsets have been
identified in HIV+ individuals, again suggesting that direct infection of resting T cells
may occur in vivo (21, 31).
If latent proviral infection can be established in naïve cells without activation,
then an alternative mechanism for why memory cells are more infected is required. One
possible mechanism is that resting memory cells are inherently more susceptible to direct
infection with HIV. This alternative mechanism should be considered given that a subset
of memory CD4+ T cells express higher levels of CCR5 (14-16) and given that memory
cells are considered to be in a more active state than naïve cells (9).
While, in our previous studies, we showed that resting CD4+ T cells could be
directly infected, we did not separate the cells into naïve and memory subsets and so did
not address whether HIV could directly infect the more quiescent naïve cells. It is
important to answer these questions because proviral persistence in naïve cells may be
regulated by factors different from those in memory cells. Therefore, therapeutic
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strategies to eliminate infection in naïve cells may be different from strategies that target
infection in memory cells.
Here we used an in vitro system in which we infected resting CD4+ T cells with
HIV by spinoculation, cultured these cells for three days, then sorted the cells into naïve
and memory resting CD4+ T cells, and assayed discrete steps in viral replication. We
present two novel findings. First, we show that naïve resting CD4+ T cells can be directly
infected by X4-HIV without prior activation. Second, we show that memory resting
CD4+ T cells are more susceptible to HIV infection than naïve cells in large part because
viral fusion occurs more efficiently in memory cells.
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Section 3.3 – Results
3.3.1 Purification of memory and naïve cells. (Figures 3.1 and 3.2)
In this study, our approach to determining the relative susceptibilities of memory
and naïve cells differed from our prior approaches, in that we sort-purified the cells three
days after inoculation. Starting with PBMCs, we isolated a mixed population of CD4+ T
cells and dendritic cells (DCs), spinoculated this mixed population with HIV, cultured for
three days, then sort-purified naïve and memory resting CD4+ T cell subsets, and assayed
for intermediates of HIV infection (Figure 3.1A). Specifically, we obtained PBMCs from
healthy donors using an IRB-approved protocol and negatively selected against CD8+
and TCR#/$ T cells, CD36+ monocytes, CD56+ and CD16+ NK cells, CD19+ B cells
and CD66b+ granulocytes using a rosette method (RosetteSep kit, StemCell
Technologies, Inc.). This negative selection protocol left us with a CD4+ T and DC
mixture. This cell mixture was spinoculated with either X4- or R5-HIV and cultured for
three days. After three days of culture, the CD4+ T and DC mixture was sort-purified into
memory and naïve resting CD4+ T cells by selecting against activation markers (HLA-
DR, CD69, and CD25) and by CD45RA and CD62L expression patterns. Our approach
sorted naïve and memory cells, as demonstrated by the post-sort analysis (Figure 3.1B):
3% of the sorted naïve cells (CD45RA(+) and CD62L(+)) were memory cells, and 3% of
the sorted memory cells (CD45RA(-) and/or CD62L(-)) were naïve cells.
We chose the approach of sorting on day 3 post-inoculation based on CD62L and
CD45RA expression for several reasons. First, by omitting positive selection of memory
and naïve T cells before inoculation we prevented unnecessary stimulation of the cells,
which could influence the susceptibility of the cells to HIV infection. Second, this
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Figure 3.1. (A) Outline of purification, infection, and sorting strategy of memory
and naïve resting CD4
+
 T cells.
(B) After resting CD4
+
 T cells were sorted, naïve cells contained 3% contaminating
memory cells and memory cells contained 3% contaminating naïve cells. The CD4
+
 cells
were sorted by selecting for CD3
+
 cells that lacked activation markers (HLA-DR, CD69,
and CD25) and had the pattern of expression of CD45RA and CD62L as shown.
Fluorescence-minus-one controls were used to place the L-shaped gate that measures the
purity of naïve and memory resting cells. The fluorescence-minus-one gates were placed
so that 1% of unstained cells appeared as stained. Less than 1% of the cells were
endogenous activated (not shown) as defined in our prior papers (24, 25).
A B
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Figure 3.2. Expression level of CCR5, CXCR4, and Ki67 in memory and naïve
resting CD4+ T cells.
The level of expression of the HIV co-receptors CCR5 and CXCR4 and the level of
expression of the cellular activation markers Ki67 was assessed by flow cytometry. A
subset of memory cells (dashed oval) expressed higher levels of CCR5 compared to the
most memory cells. Minimal expression of the cell cycle marker Ki67 was detected in the
memory subset and no expression was detected in the naïve cells. Unstained cells were
used to show the background level for CXCR4 and CCR5 staining. An isotype control
was used to determine the background level for the Ki67 intracellular staining.
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strategy allowed us to ask later whether the presence of DCs enhances infection of naïve
or memory CD4+ T cells. Lastly, in the two studies which showed that in vivo memory
cells have higher levels of integrated HIV DNA than naïve cells, CD62L and CD45RA
expression were used to define memory and naïve CD4+ T cell subsets (21, 32).
We also wanted to determine the expression levels of CXCR4, CCR5, and Ki67
on naïve and memory cells at the time of inoculation to determine the levels in our
system. We were also interested to determine if significant levels of Ki67 were expressed
in our purified naïve and memory resting CD4+ T cells, since this has been described as a
marker for actively cycling cells (33-35). To do this, we removed an aliquot of the CD4+
T and DC mixture prior to spinoculation, sort purified the cells into naïve and memory
resting CD4+ T cells (using CD62L and CD45RA, CD3 and activation markers). We
then stained the sorted aliquot with antibodies against surface CXCR4, CCR5, and
intracellular Ki67, and analyzed the level of expression in memory and naïve resting
CD4+ T cells (Figure 3.1A). Consistent with other reports (14, 16, 36), we found that the
level of CXCR4 was slightly higher on naïve cells (Figure 3.2). We also found that a
subset of memory cells expressed higher levels of CCR5 as previously described (14, 16,
37, 38) (Figure 3.2). Ki67 expression was undetectable on naïve cells and present at very
low levels in memory cells (Figure 3.2).
3.3.2 Higher levels of integration in memory cells than in naïve cells. (Figures 3.3,
3.4 and 3.5)
In comparing naïve and memory resting cells, the first step of the viral life cycle
that we investigated was integration. As described in Figure 3.1A, we inoculated cells
with HIV, cultured for three days, sort-purified naïve and memory cells, and then
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quantified the level of integration (24-26). We assayed integration after the inoculated
cells were cultured for three days because we previously showed that the level of
integration plateaus at that time point (24-26). We found that integration was detectable
in naïve cells inoculated with X4-tropic HIV (pNL4-3) (Figure 3.3, open bars). The level
of integration in R5- and X4-inoculated memory cells was higher than that in naïve cells
(Figure 3.3). When we averaged the ratio of memory over naïve integration level, we
found on average 36-fold higher integration with R5-HIV (but the ratio ranged from 10-
73 fold higher) and 4-fold higher with X4-HIV. We cannot determine conclusively
whether R5-HIV can directly integrate into naïve cells, because the signal is close to the
signal expected from contaminating memory cells. Nonetheless, we can conclude that
X4-HIV directly integrates into naïve cells since 25% contaminating memory cells would
be required to account for the signal obtained in the naïve subset.
Since integration occurred at higher levels in memory cells, we wanted to test two
possible explanations. One, DCs have been described to enhance CD4+ T cell infection
(39), thus DCs present during the inoculation and culture might preferentially activate the
memory cells. Furthermore, it is known that the requirements for activation of memory
cells differ from the requirements of naïve cells (11). Two, nucleotide levels may be more
limiting in naïve cells compared to memory cells (26).
Next, we asked whether the difference in integration levels between memory and
naïve cells was altered by co-culturing CD4+ T cells with DCs. To test this, we modified
the protocol described in Figure 3.1A in the following ways: after preparing a CD4+ T
and DC mixture, we either depleted or did not deplete DCs (defined as BDCA1 and
BDCA4+ cells). Before depletion, DCs comprised 0.89% of the CD4+ T and DC
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Figure 3.3. X4-HIV integration is detected in naïve resting CD4+ T cells but at lower
levels than memory resting CD4+ T cells.
CD4+ T cells were infected by spinoculation with R5-HIV (n=2 for pRF-1 and n=2 for
BaL) or X4-HIV (pNL4-3), cultured for 3 days and sorted into naïve and memory resting
cells. Integration (proviruses/cell) was measured by Alu-PCR. Dashed line represents the
expected level of integration from contaminating memory cells (3% contaminants). The
bars represent the average of 4 independent R5 experiments and 5 independent X4
experiments. Error bars represent the standard error. Integration was measured 2-4 times
in each independent experiment. The p values were calculated with the Wilcoxon rank-
sum test.
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Figure 3.4. The presence of endogenous, unstimulated dendritic cells does not
influence the susceptibility of resting naïve or memory cells.
(A) FACS analysis of spinoculated cells before and after DC depletion. CD4+ T and
dendritic cell mixtures were exposed to anti-BDCA-1 and anti-BDCA-4 PE-labeled
antibodies followed by depletion of BDCA-1 and -4(+) dendritic cells with anti-PE
beads. The cells were then analyzed for the presence of dendritic cells and T cells by
staining with anti-BDCA1, 4 and CD3 antibodies. (B, C) CD4+ cells depleted or not
depleted of endogenous dendritic cells, were infected with BaL (R5-HIV) or pNL4-3
(X4-HIV) by spinoculation. At 3 days post-inoculation, resting naïve and memory were
sorted and integration (proviruses/cell) was measured by Alu-PCR. Error bars represent
the standard deviation of three to four measurements of integration. The p values were
calculated with the Wilcoxon rank-sum test. Similar results were obtained when the DCs




Figure 3.5. Limiting deoxynucleosides are not responsible for lower susceptibility of
naïve resting cells to HIV integration compared to memory resting CD4+ T cells.
CD4+ T cells were infected with pNL4-3 (X4-HIV) by spinoculation, followed by culture
for 3 days and then sorted into naïve and memory resting CD4+ T cells. The inoculation
and culture of the cells was conducted in the presence or absence of 50µM of
deoxynucleosides (dN). Integration (proviruses/cell) was measured by Alu-PCR. Error
bars represent the standard deviation of three measurements of integration.
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mixture; after depletion DCs comprised ~0.02% of the mixture (Figure 3.4A). The two
cell preparations were then spinoculated with HIV, cultured for three days, sort purified
into memory and naïve resting subsets, and the level of integrated DNA was measured.
We found that depletion of DCs had no apparent effect on the integration levels of R5 or
X4 virus in either naïve or memory CD4+ T cells (Figure 3.4B). Therefore, we conclude
that the presence of endogenous, unstimulated DCs does not affect the susceptibility of
naïve or memory resting CD4+ T cells and that the presence of DCs is not responsible for
the higher susceptibility of memory cells to HIV infection compared to naïve cells.
Because we had previously demonstrated that the addition of deoxynucleosides
(dNs) enhanced integration in resting CD4+ T cells (26), here we asked whether adding
dNs enhanced integration in naïve cells only or in both memory and naïve resting CD4+
T cells. In a modification of the protocol shown in Figure 3.1A, we either added or did
not add dNs to the CD4+ T and DC mixture at the time of spinoculation. After three days
of culture, the level of integration was assayed in sort-purified naïve and memory resting
CD4+ T cells. We observed that the addition of dNs increased the level of integration in
both populations similarly – ~4-fold (3.3-fold for memory and 4.0-fold for naïve) (Figure
3.5).  We concluded that the relative difference between naïve and memory cells was not
altered by the addition of dNs and that the difference in susceptibility cannot be attributed
to nucleotide pools (Figure 3.5).
3.3.3 Higher levels of fusion to memory cells than to naïve cells. (Figures 3.6 and 3.7)
Given that neither deoxynucleoside pools nor the presence of dendritic cells could
explain the higher levels of HIV integration in memory compared to naïve cells (Figure
3.3), we next asked which steps were more restricted in naïve cells. We decided to start
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from the beginning of the life cycle and test the level of fusion and then the level of
reverse transcription in both cell types. To compare HIV fusion in memory and naïve
cells, we used the BlaM-Vpr fusion assay (40, 41). In this assay, virions are loaded with
%-lactamase that is covenlently linked to Vpr and the cells are loaded with the %-
lactamase substrate CCF2-AM, a dye that fluoresces green. When %-lactamase-
containing virions fuse to CCF2-dyed cells, %-lactamase cleaves CCF2, causing a change
in cellular fluorescence from green to blue that can be detected and quantitated by FACS
(40). Notably, this assay measures fusion and not viral uncoating since CCF2 can still be
cleaved in intact viral cores (42). In other words, BlaM-Vpr will be able to cleave CCF2
after viral fusion regardless of whether or not the virus has uncoated. To validate the
assay we measured viral fusion to resting CD4+ T cells in the presence or absence of the
fusion inhibitor enfurvitide (T-20) (Supplement S3.1). When we compared viral fusion to
memory and naïve cells using R5-HIV, we found that virus fused to 0.8% of naïve cells
and fused to 5.3% of memory cells (Figure 3.6). Percent fusion was calculated by
subtracting the background % blue in uninfected cells from the % blue cells in infected
cells (e.g. for naïve cells 1.3 - 0.5 = 0.8%, for memory cells 5.8 – 0.5 = 5.3%). When we
performed this experiment using X4-HIV, we found that 5.8% of naïve cells fused with
the HIV virions and 21.9% of memory cells fused with the HIV virions (Figure 3.6).
Because viral binding precedes viral fusion, the differences we observed in viral
fusion between naïve and memory cells could have been due to differences in viral
binding, although this is unlikely since both cell types express similar levels of CD4. To
address this possibility, we estimated the level of viral binding to naïve and memory




inoculation. Similar to Figure 3.1B, naïve and memory resting CD4+ T cells were sort-
purified from CD4+ T cells based on the expression of CD45RA and CD62L, and the
absence of the activation markers CD25, CD69, and HLA-DR. Following sort-
purification, naïve and memory resting cells were spinoculated with R5- or X4-HIV.
After inoculation, the cells were washed to remove unbound virions and the level of cell-
associated p24
Gag
 was measured by ELISA. We found that the level of viral binding to
naïve cells was equal to the level of binding to memory cells for both R5- and X4-HIV
(Figure 3.7), suggesting that the difference in viral fusion that we see between naïve and
memory cells cannot be attributed to differences in viral binding. We note that fusion
may occur during our spinoculation procedure at 25°C, especially to memory CD4+ T
cells, and that this may affect the level of viral binding that we detect. However, given
that we saw similar viral binding to both memory and naïve cells, any effect of viral
fusion during spinoculation on binding is likely to be below the detection limit of our
binding assay.
In summary, compared to naïve cells, we detected 7-fold more fusion in R5-
inoculated memory cells and 4-fold more fusion in X4-inoculated memory cells. Given
that naïve cells express slightly more CXCR4 than memory cells, we were surprised to
find that X4 viruses fused more efficiently to memory cells than naïve cells. From these
data we concluded that fusion of both X4- and R5-HIV occurs more readily to memory
than naïve resting CD4+ T cells. In other words, it appears that naïve cells are relatively
restricted at fusion.
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Figure 3.6. Fusion of R5- and X4-tropic HIV is less efficient to naïve compared to
memory resting CD4+ T cells.
CD4+ T and DC mixtures were spinoculated with either (B) pNL-AD8 (R5-HIV) or (D)
pNL4-3 (X4-HIV) particles that carry BlaM-Vpr. After inoculation the cells were loaded
with the dye CCF2-AM. Uninfected cells (A, C) loaded with CCF2-AM were used as a
negative control for each inoculation. After infecting the cells with (B) R5-HIV or (D)
X4-HIV, naïve and memory resting CD4+ T cells were gated for cells that had taken up
the green dye and fusion was measured based on the percentage of cells that fluoresce
blue. Fusion was measured independently among the naïve (CD45RA(+) CD62L(+)) and
memory (CD45RA(-) and/or CD62L(-)) subsets of resting CD4+ T cells (CD69, CD25




Figure 3.7. Both R5 and X4-HIV bind equally to naïve and memory resting CD4+ T
cells.
Sorted naïve (CD45RA(+) CD62L(+)) and memory (CD45RA(-) and/or CD62L(-))
resting CD4+ T cells were spinoculated with BaL (R5-HIV) and pNL4-3 (X4-HIV) for 2
hours at 25°C. The level of viral binding was estimated by measuring the level of cell-
associated p24
Gag
 by ELISA immediately after inoculation and after removal of unbound
virions. The graph represents the average of a total of 6 measurements of viral binding
from 3 independent inoculations. Error bars represent the standard error. The p values
were calculated with the Wilcoxon rank-sum test.
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3.3.4 Higher levels of reverse transcription in memory cells than naïve cells. (Figure
3.8)
Finally, we wanted to assess if there are differences in HIV reverse transcription
efficiency between naïve and memory resting CD4+ T cells that could contribute to the
differences in susceptibility of these cell subsets to HIV infection. To do this, we
compared reverse transcription of HIV in memory cells and naïve cells, by measuring the
level of reverse transcription that has completed the second-strand transfer (SST) and by
calculating the fraction of those reverse transcripts that integrated (proviruses/SST or
integrated HIV DNA/total HIV DNA). We found on average 20-fold more R5 reverse
transcripts and 4-fold more X4 reverse transcripts in memory cells than in naïve cells
(Figure 3.8A). This difference paralleled that seen with integration (Figure 3.3).
Reverse transcription may also occur less efficiently in naïve compared to
memory cells. However, the differences in reverse transcription efficiency between
memory and naïve cells if present are modest and so difficult to quantitate.
When we calculated the fraction of reverse transcripts that integrated in the naïve
and memory subsets (-proviruses/SST- by dividing the data in Figure 3.3 with the data in
Figure 3.8A), we found that the fractions were comparable: in both subsets with both X4-
and R5-HIV infection (Figure 3.8B). There was no statistical difference between memory
and naïve resting CD4+ T cells when we averaged experiments (Figure 3.8B, n=4 for R5
and n=5 for X4). This finding suggests that the susceptibility to infection of memory and
naïve CD4+ T cells is not determined at the level of integration, and that integration is
not impaired in naïve T cells.
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Figure 3.8. HIV reverse transcription is less efficient in naïve compared to memory
resting CD4+ T cells.
The efficiency of integration (proviruses/SST) is similar in both naïve and memory
resting CD4+ T cells. CD4+ T and DC mixtures were infected with an R5-HIV (BaL for
2 experiments and pRF1 for 2 experiments) or an X4-HIV (pNL4-3) (5 experiments) by
spinoculation and cultured for 3 days and then sorted into naïve and memory resting
CD4+ T cells. (A) Late reverse transcription was measured by quantitative PCR, using
primers that detect the second strand transfer of reverse transcription (SST). (B) The
ratios of integration by total DNA (proviruses/SST) were obtained by dividing the data in
(Figure 3.3) by the data in (A). Error bars represent the standard error of 4 (R5) and 5





Figure 3.9. VSV-G pseudotyped HIV infects both naïve and memory resting CD4+
T cells with similar efficiency.
CD4+ T cells were infected with RF-1 (R5-HIV) or pNL4-3 (X4-HIV) particles
pseudotyped with VSV-G by spinoculation, followed by culture and were sorted into
naïve and memory resting CD4+ T cells. Integration was measured as in Figures 3.3-3.5.
Error bars represent the standard error of two independent experiments. The p values
were calculated with the Wilcoxon rank-sum test. The X4-HIV(VSV-G) used for these
experiments is 5 times more potent than the R5-HIV(VSV-G) as assessed by the level of
reverse transcripts present in CEM-ss cells 24 hours after a single round infection.
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3.3.5 VSV-G pseudotyped HIV integrates into the genome of naïve and memory
resting CD4+ T cells to similar extents. (Figure 3.9)
We then hypothesized that if memory cells are “more infected” because naïve
cells are restricted at fusion, then pseudotyping HIV with VSV-G envelope should
overcome this restriction. This reasoning was based on the expectation that VSV-G-
pseudotyped HIV would fuse to naïve and memory cells to similar extents given the
ubiquitous nature of the VSV-G receptor (43). First, we tested if pseudotyping HIV with
VSV-G enhanced infection of naïve cells. To do this, we spinoculated the CD4+ T cell
and DC mixture with R5-HIV(VSV-G) or X4-HIV(VSV-G), cultured for three days,
sorted the cells into subsets, then assayed integration. We found that the levels of
integration of R5- or X4-HIV(VSV-G) in naïve and memory cells were comparable and
not statistically different (Figure 3.9) (p = 0.4 for R5 virus and p = 0.2 for X4 virus). The
observation that pseudotyping HIV with VSV-G resulted in comparable levels of
integrated DNA strongly suggests that naïve cells, relative to memory cells, are largely
restricted at HIV fusion and possibly modestly restricted at reverse transcription. Stated
another way, memory cells are inherently more susceptible to HIV fusion by both X4 and
R5 viruses.
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Section 3.4 – Discussion
In the present study, we show for the first time that X4-HIV can directly integrate
into the genomes of naïve resting CD4+ T cells without prior activation of the cells.
Although prior work demonstrated that resting CD4+ T cells are susceptible to HIV
integration (24-27) and although it is known that naïve cells represent 30-70% of CD4+ T
cells in blood, it was possible that all the integrated DNA was in the memory subset.
Thus, the susceptibility of naïve cells to HIV integration compared to memory cells was
unclear. Consistent with in vivo data, the memory resting CD4+ T cells are inherently
more susceptible to HIV infection than naïve resting CD4+ T cells. We also show for the
first time that the enhanced susceptibility of memory cells is due, in large part, to more
efficient HIV fusion to memory compared to naïve resting CD4+ T cells (Figure 3.6).
Reverse transcription may also occur slightly more efficiently in memory resting cells,
but this effect is modest. Integration, on the other hand, occurs with similar efficiency in
both cell types with both R5 and X4 viruses based on ratios of proviruses/SST (Figure
3.8B), suggesting that integration is not impaired in naïve resting cells compared to
memory resting cells. In addition, we show that deoxynucleosides enhance infection in
both cell types to similar extents suggesting that nucleotide pools are equally limiting in
both cell types. Finally, we show that coculture of endogenous unstimulated blood DCs
does not enhance infection of either naïve or memory CD4+ T cells.
Our approach was to sort resting CD4+ T cells into naïve and memory subsets
three days after inoculation and then to assay integration in naïve and memory cells. This
approach prevented unnecessary stimulation of the resting cells by cross-linking
antibodies prior to infection. By carefully accounting for the contaminating memory cells
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in the purified naïve cell fractions, in Figure 3.3, we were able to show that X4- and R5-
HIV viruses were able to directly integrate into naïve resting CD4+ T cells. We
acknowledge that in some experiments (for example Figure 3.4), the lower levels of
integration of R5 in the naïve cells could be due to residual contaminating memory cells.
However, our data clearly demonstrate that X4 viruses were able to directly integrate into
naïve resting CD4+ T cells and that this signal was not due to contaminating memory
cells.
3.4.1 Role of dendritic cells. We also showed that co-inoculation of endogenous blood
DCs does not enhance the level of HIV integration in naïve or memory cells. This is in
agreement with studies by Hladik, et al. (44), but appears to contradict prior studies (39).
However, in many of the reviewed studies (39), trans-infections rather than co-infections
were performed. In other words, the DCs were usually first isolated, then activated,
followed by exposure to HIV, and finally co-cultured with T cells. Our studies and the
studies of Hladik, et al. (44), looked at the role of DCs during co-inoculation without
prior activation of the DCs and found no enhancement of infection of the T cells through
the presence of DCs. Thus, cell-mediated stimuli are not required for infection of resting
naïve cells.
3.4.2 Role of nucleotide levels. We also explored the possibility that the reduced level of
integration seen in naïve cells could have been due to lower nucleotide pools in these
cells given that naïve cells are considered to be more quiescent (9). We previously
showed that deoxynucleoside addition enhances the level of integration (26).  However,
we found that supplying deoxynucleosides exogenously enhanced integration of both cell
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types equally. This suggests that nucleotides are limiting in both cell types and does not
explain the difference in susceptibility between naïve and memory T cells.
3.4.3 Role of activation status. We were interested in determining whether Ki67 levels
on cells correlated with susceptibility to HIV infection. We found that HIV can integrate
into the genomes of Ki67-negative, non-cycling naïve cells. Low levels of Ki67 were
detected on resting memory cells consistent with the idea that these cells are slightly
more activated than naïve cells or at a slightly different stage in the cell cycle. It has been
reported that memory cells are in G1a and naïve cells in G0 based on levels of RNA (9).
We speculate that the level of Ki67 may correlate with a T cell’s susceptibility to HIV,
although the significance is unclear.
3.4.4 Fusion. We also showed that the difference in infection between memory and naïve
cells was largely due to fusion efficiency (Figures 3.6-3.9). We did this by measuring
viral fusion immediately after inoculation. For example, X4 viruses fused 4 times more
efficiently to memory compared to naïve cells, while R5 viruses fused 7 times more
efficiently to memory over naïve. Importantly, one would expect X4 viruses to fuse to
naïve more than memory given that naïve cells express slightly more CXCR4 than
memory ((14-16), also see Figure 3.2), but the opposite occurs. Finally, we confirmed
that the higher susceptibility of memory cells to HIV infection is mostly due to more
efficient viral fusion compared to naïve cells, by pseudotyping HIV particles with VSV-
G envelope. We found that the difference in HIV integration level between memory and
naïve was greatly reduced when particles carried VSV-G envelope, which is thought to
have a ubiquitous receptor.
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3.4.5 Potential mechanism for enhanced fusion to memory cells. In the case of R5
infection, the increased susceptibility of memory cells could simply be due to higher
CCR5 levels, but in the case of X4 infection, other explanations are required since the
level of CXCR4 is slightly higher on naïve cells. One explanation could be that naïve
cells may express different conformations of the chemokine receptor (45) that may not
allow fusion as efficiently as the conformations found in memory cells. Another
explanation is that some form of virus-induced cellular stimulation could enhance fusion
and naïve cells may require a higher threshold of virus-mediated stimulation (9-12). For
example, more HIV receptors or co-receptors may need to be engaged for fusion to occur
to naïve cells.  Finally engaging the co-receptors may enhance fusion through signaling in
naïve cells to a greater extent than in memory cells.  Most studies suggest that co-receptor
signaling is not necessary for HIV fusion (46-50), but one recent study suggests that
signaling can play a role in one model of HIV envelope mediated cell-to-cell fusion (51).
Here we addressed the relative susceptibility of naïve and memory resting CD4+
T cells and which replication step determines susceptibility. Prior studies only compared
the relative susceptibility of naïve and memory cells after activating the cells to divide
and only studied relative levels of reverse transcription and production (52-56). We found
that, consistent with SIV and HIV in vivo infection (28, 30, 57, 58), memory cells are
more susceptible to fusion with both X4 and R5 viruses, but HIV can directly infect and
integrate into the genomes of both cell types. These experiments support our previous
finding that cells in G0/G1a can be infected by HIV (24, 25). We emphasize that our
results do not disagree with prior work showing restrictions at reverse transcription and
integration within 24 hours of infection (3-5, 7, 55, 59). We only detect significant levels
91
of integration 2-3 days after infection (26, 60). In other words, the restriction in resting
CD4+ T cells alters the tempo of infection, but not the final outcome – integration of HIV
into the host genome. Our results provide further support for an alternative mechanism
for how HIV proviruses establish latent infection - by direct infection of resting CD4+ T
cells.
Our results are consistent with the model that proviruses may establish latent
infection by direct infection of resting CD4+ T cells (24-27). Thus, proviruses may
establish latent infection in the absence of an activation step. One argument for a model
of direct infection of resting CD4+ T cells is that the ratio of infected memory and naïve
cells in blood of HIV infected individuals and in our in vitro model are similar:
approximately ~16-fold more integrated DNA is found in memory cells from HIV
infected individuals (21). Another argument for direct infection is that resting cells have a
much longer half-life than activated cells (61-64). Notably, naïve resting CD4+ T cells
have a longer half-life than memory resting CD4+ T cells, which in turn have a longer
half-life than activated CD4+ T cells.  Infected resting CD4+ T cells are likely to
continue to have a survival advantage over infected activated CD4+ T cells, since
activated CD4+ T cells produce more infectious virus than resting CD4+ T cells which
likely shortens the lifespan of the infected activated cells to a greater extent that the
infected resting cells (29, 31, 61, 65). Furthermore, the predominance of infected
“apparently” resting memory cells in acute infection suggests direct infection of resting
cells occurs in vivo (30, 58). Thus, our data, taken together with T cell turnover data and
in vivo studies of acute infection, suggest that direct infection of naïve and memory
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resting CD4+ T cells by HIV may be an important mechanism whereby HIV proviruses
establish latent infection in vivo.
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Section 3.5 – Materials and Methods
3.5.1 Cell lines, plasmids, and viruses. The CD4+ T-lymphoblastoid cell line CEM-ss
(66, 67) was maintained at 1-5x 10
5
 cells/ml. The culture medium used was RPMI 1640
supplemented with 10% heat-inactivated FBS, 25 mm HEPES, and 100ug/ml penicillin-
streptomycin (Invitrogen Life Technologies). Virions were collected 48 hours after
calcium-phosphate transfection of 293 T cells. Viral supernatants with peak reverse
transcription activity were treated with DNase I at 30 µg/ml (Roche Molecular
Biochemicals, Indianapolis, Indiana) for 1hr at 37°C. pNL4-3 transfection supernatants
(68)(donated to the AIDS Reagents Program by Dr. Malcolm Martin), pRF1 transfection
supernatants or the CCR5-tropic viral isolate BaL (69) (purchased from the Center for
AIDS Research core facility at the University of Pennsylvania) were used to generate the
data for Figures 3.3-3.5 and 7-8. pRF1 (a gift from Dr. Michael Malim) is equivalent to
pYU2 except that a mutation in Vpu is corrected (70). pNL4-3 and pNL-AD8
(71)(donated to the AIDS Reagents Program by Dr. Eric O. Freed) were co-transfected
with BlaM-Vpr (40, 41) (donated by Dr. Michael Miller to the AIDS Reagents Program)
to generate virus for Figure 3.6. pNL4-3 and pRF1 were co-transfected with VSV-G
(pHIT) (70) to generate Figure 3.9. Viral potency was based on the level of reverse
transcription (Second Strand Transfer, SST) in CEM-ss cells 24 hours after infection in a
single cycle infection using saquinavir to prevent spreading infection.
3.5.2 Reagents. PE-, FITC-, PerCp-, APC-, or APC-Cy7-conjugated monoclonal
antibodies were purchased from Becton Dickinson (Sunnyvale, CA): CD45RA, CD3,
CD62L, HLA-DR, CD69, and CD25, CXCR4, CCR5, Ki67. PE-conjugated BDCA-1,
BDCA-4, and anti-PE magnetic beads were obtained from Miltenyi Biotec Inc. (Auburn,
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CA). Saquinavir was used at 1.25µM (Roche US Pharmaceuticals). Deoxynucleosides
were purchased from Sigma-Aldrich (St. Louis, MO). The CCF2-AM staining kit used
for measuring HIV fusion was purchased from Invitrogen.
3.5.3 Preparation and Purification of CD4+ cells and T cell subsets. CD4+ cells were
isolated by negative selection from leukapheresis-enriched PBMC using the
RosetteSep
TM
 kit (StemCell Techologies, Inc) as recommended by the manufacturer.
Briefly, leukapheresis-enriched PBMC were labeled with antibodies recognizing
Glycophorin A, CD8, CD16, CD19, CD36, CD56, CD66b, TCR#$. A secondary anti-
mouse antibody was added to cross-link labeled PBMC to labeled red blood cells.
Following these labeling steps, the cells were applied to a Ficoll-Paque (GE Healthcare)
density gradient to remove the cross-linked cell complexes. This purification step
normally yields CD4+ T and dendritic cell mixture. DC-depleted CD4+ cells were then
isolated by negative selection with saturating concentrations of PE-labeled antibodies
specific for BDCA-1 and BDCA-4 and anti-PE magnetic beads as recommended by the
manufacturers. Immediately after DC depletion, the levels of DCs present were
determined using antibodies against BDCA1 and 4 and CD3. After 3 days of culture of
the spinoculated cells, T cell subsets were isolated from the cultures with or without DC
depletion. To do this, the cells were labeled with FITC-labeled CD45RA, PE-labeled
HLA-DR, CD25, CD69, APC-labeled-CD62L and APC Cy7-labeled CD3. Naïve and
memory T cells were sorted based on CD3, CD62L and CD45RA expression and lack of
activation markers (HLA-DR, CD69, CD25).
3.5.4 Flow cytometry. To determine the level of the co-receptors CCR5 and CXCR4 and
Ki67, we sort purified an aliquot of naïve and memory cells on the day of inoculation.
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The co-receptor levels were determined by surface staining in FACS buffer (PBS with
1%BSA and 2mM EDTA) and blocking non-specific binding with mouse IgG. For cell
proliferation marker Ki67 staining, the purified T cell subsets were first fixed by 70%
ethanol, followed by intracellular staining with PE-labeled Ki67 as recommended by the
manufacturer. The results were analyzed with FlowJo software (Treestar).
3.5.5 HIV infection of human primary cells. All the cells were cultured in RPMI 1640
media containing 10% heat-inactivated FBS, supplemented with 2mM L-glutamine, 100
µg/ml penicillin-streptomycin and 25mM HEPES prior to infection. Cells diluted at
1x10
7
cells/ml in viral supernatant, were spinoculated at 1200xg for 2hr at 25°C as
similarly described (72). When testing the effect of deoxynucleosides on integration, cells
were resuspended with both the appropriate virus and a deoxynucleoside mixture at
50µM (at equal content of each deoxynucleoside) and spinoculated. After spinoculation,
the cells were washed 3 times to remove unbound virions, resuspended in medium in the
presence of 1.25µM Saquinavir, 50µM of deoxynucleosides (when indicated) and
incubated at 37°C.
3.5.6 Real-time PCR analysis for viral DNA intermediates. DNA was prepared after
HIV infection using the QIAmp Blood and Cell Culture Kit (Qiagen, Valencia,
California). Real-time PCR was performed to detect long reverse transcripts (completed
second strand transfer -SST-), integrated HIV DNA and %-globin as described (24, 25,
73).
3.5.7 Fusion assay. Transfection supernatants of pNL4-3 or pNL-AD8 viruses containing
BlaM-Vpr were utilized to inoculate pure resting CD4+ T cells by spinoculation at
1200xg for 2hr and at 25°C. After inoculation, the cells were washed twice with cold
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PBS + 10%FBS to remove unbound virions. Cells were then resuspended in RPMI +
10% FBS and incubated at 37°C for 30 mins to induce viral fusion. After fusion, cells
were washed twice with CO2-independent medium (Invitrogen) without serum and
without antibiotics. A stock CCF2-AM loading solution was prepared for staining the
cells: 2µl of CCF2 at 200µg/ml and 8µl of 100 mg/mL Pluronic-F127 surfactant in
DMSO and 0.1% acetic acid, diluted to a total of 1ml with CO2-independent medium
without antibiotics or serum. One million cells were resuspended in 100µl of CCF2
loading solution and incubated at room temperature for 1hr to allow dye uptake. Cells
were subsequently washed with CO2-independent medium, resuspended in CO2-
independent medium containing 10% FBS and 2.5mM of probenecid (Sigma-Aldrich)
and incubated at 25°C for ~12hr. After incubation at 25°C, the cells were washed once
with FACS buffer and stained for the following markers: activation markers (HLA-DR,
CD69, CD25), CD4, CD62L and CD45RA. Stained cells were then analyzed by
multicolor flow cytometry using a BD™ LSR II flow cytometer.
3.5.8 Measuring viral binding. Viral binding was estimated by measuring the level of
cell-associated p24
Gag
 immediately after inoculation using a p24-specific ELISA (Perkin
Elmer). The approximate number of viral particles bound per cell was calculated as
previously described (25, 72).
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Section 4.1 – Abstract
Current gene transfer protocols for resting CD4+ T cells include an activation step to
enhance transduction efficiency. This step is performed because it is thought that resting
cells are resistant to transduction by lentiviral-based gene therapy vectors. However,
activating resting cells prior to transduction alters their physiology with foreseeable and
unforeseeable negative consequences. Thus, it would be desirable to transduce resting
CD4+ T cells without activation. We recently demonstrated, contrary to the prevailing
belief, that wild-type HIV integrates into resting CD4+ T cells. Based on that finding, we
investigated whether a commonly used, VSV-G-pseudotyped lentiviral gene therapy
vector could also integrate into resting CD4+ T cells. To investigate this, we inoculated
resting CD4+ T cells with lentiviral particles that were pseudotyped with VSV-G or
CXCR4-tropic HIV Env and assayed binding, fusion, reverse transcription, and
integration. We found that the VSV-G-pseudotyped lentiviral vector failed to fuse to
resting CD4+ T cells, while HIV Env-pseudotyped lentiviral vectors fused, reverse
transcribed, and integrated in resting cells. Our findings suggest that HIV Env could be
used effectively for the delivery of therapeutic genes to resting CD4+ T cells and suggest
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that fusion at the plasma membrane may be the critical step restricting transduction of
resting CD4+ T cells by lentiviral gene therapy vectors.
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Section 4.2 – Introduction
With the sequencing of the human genome, gene therapy is becoming an
important intervention into the therapy of many diseases including immunological
disorders, certain cancers, and even HIV infection (1-3). However, two very important
requirements must be met for any gene therapy strategy to be effective: efficient delivery
of the gene of interest to the target cell population and significant longevity of the target
cell population in the host.
Lentiviral-based vectors are commonly used in gene therapy studies due to their
ability to transduce most non-dividing cell types (4-6). To deliver these vectors to target
cells, lentiviral vectors can be pseudotyped with viral envelopes that can mediate entry
into the cell type of choice (7). A popular example of such an envelope is the vesicular
stomatitis virus g-glycoprotein (VSV-G) (4-6). This envelope has been widely used for
pseudotyping lentiviral vectors due to its very broad tropism, allowing entry of viral
particles into most cell types that have been tested (8).
Cells in the G0 stage of the cell cycle, such as resting CD4+ T cells and hematopoietic
stem cells, are desirable targets for genetic therapy due to their long life span in the host.
However, G0 CD4+ T cells (9-16), similar to G0 hematopoietic stem cells (10), are
thought to resist lentiviral-mediated transduction. For this reason, current gene therapy
protocols that target G0 T lymphocytes include activation of the target cells before
transduction (1). However, activating cells prior to transduction alters the natural
physiology of the target cells (17). Activation and expansion of cells prior to lentiviral
transduction may skew the cell population to a memory phenotype, may skew them to a
Th1 response (18), may affect their immune competence (briefly reviewed by Marktel, et
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al. (18)), and possibly affect telomere length (19), which in turn may shorten the
longevity of the transduced cells. These phenotypic and physiological changes that occur
upon in vitro activation of cells may lead to unforeseeable outcomes that may affect the
efficacy of the gene therapy. Furthermore, current transduction protocols expand the T
cells over several generations and thus are time consuming and expensive.
Given these pitfalls, it would be useful to directly transduce G0 T lymphocytes
without activating them. In addition, transduction of G0 lymphocytes would also offer
additional approaches to study the biology of the immune system and retroviruses. For
example, transducing resting CD4+ T cells ex vivo would allow one to study the effect of
specific gene expression in a more physiological setting.
Contrary to the prevailing belief in the field, we have recently demonstrated that HIV
can directly integrate into the genome of resting CD4+ T cells, albeit with slower kinetics
than in activated CD4+ T cells (20-22). Our findings were recently confirmed by Vatakis,
et al (23). Furthermore, over the course of several days in culture, the transduction level
in resting CD4+ T cells approaches the level seen in activated cells during a single round
of infection. This led us to ask if a commonly used, VSV-G-pseudotyped HIV-based
lentiviral vector could also transduce resting CD4+ T cells directly. To do this, we
investigated the efficiency of the early steps involved in transduction of resting CD4+ T
cells by the lentiviral vector.
Here, we report that a commonly used, VSV-G-pseudotyped, lentiviral vector does
not transduce resting CD4+ T cells. We found that the block to infection of resting CD4+
T cells by this lentiviral vector is due to the inability of VSV-G to mediate fusion of the
viral particles to resting cells. Moreover, the use of CXCR4-tropic (X4-tropic) HIV
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envelope, in place of VSV-G, overcomes the block to infection, ultimately leading to
integration of the vector in the genomes of resting CD4+ T cells. Notably, these viral
envelopes use different cell entry mechanisms: VSV-G is endocytosis- and low pH-
dependent while HIV envelope mediates viral fusion at the plasma membrane and it is
pH-independent. These differences raise the possibility that viral cell-entry mechanisms
may be important for understanding resting CD4+ T cell susceptibility to lentiviral
infection. Our findings suggest that X4-tropic HIV envelope can be used as an alternative
envelope for pseudotyping lentiviral vectors to transduce resting CD4+ T cells.
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Section 4.3 – Results
4.3.1 A commonly-used, HIV-based gene therapy vector fails to infect resting CD4+
T cells as assessed by reverse transcription. (Figures 4.1 and 4.2)
Given the recent finding that resting CD4+ T cells can be directly transduced by
HIV (20-23), we sought to determine whether a commonly used lentiviral vector could
also transduce these cells. To do this, we used the HIV-based gene therapy vector,
VRX494 (which we will refer to as HIVvector throughout this paper) (Figure 4.2A) (24,
25). This vector is deleted for all essential and auxiliary HIV proteins, encodes GFP and
is pseudotyped with VSV-G. We inoculated unstimualted CD4+ T cells (Figure 4.1) and
the activated T cell line CEMss with wild-type (wt) HIV or HIVvector(VSV-G). CEMss
cells have similar susceptibility to HIV infection as stimulated CD4+ T cells.
Unstimulated cells were purified from enriched PBMCs by red blood cell rosette, which
separates CD4+ T cells from other T cell types, B cells, NK cells, granulocytes and
monocytes. Most unstimulated cells are considered to be in the G0/G1a stage of the cell
cycle (Figure 4.1C) (26), but a significant proportion of these cells express activation
markers (Figure 4.1A). We assayed reverse transcription by quantitative PCR using
primers that detect the second-strand transfer step of reverse transcription (SST) (Figure
4.2B, C) (27).
We found no detectable reverse transcription by HIVvector(VSV-G) in
unstimulated CD4+ T cells while we detected increasing levels of reverse transcription
over time with wtHIV (Figure 4.2B).  In contrast, the levels of reverse transcription of
HIVvector(VSV-G) and wtHIV were similar in CEMss cells (Figure 4.2C). Thus, an
early step in the infection of unstimulated CD4+ T cells with HIVvector(VSV-G) is
impaired.
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Figure 4.1. Cell activation and cell cycle profile of unstimulated and resting CD4+ T
cells.
Resting CD4+ T cells were purified from unstimulated CD4+ T cells by depletion of
CD25, CD69 and HLA-DR positive cells as described in Materials and Methods. (A)
Expression of these activation markers was monitored by flow cytometry before and after
purification. Gates were set based on a 1% background signal in a fluorescence-minus-
one (FMO) control. This control is stained for CD4 but not for the activation markers
CD25, CD69, and HLA-DR and it is used to determine more accurately the background
signal detected in the activation marker gate. (B) PBMC stimulated with PHA were
stained with pyronin Y and 7AAD to establish the stages of the cell cycle. The G1a gate
was established based on PBMC treated with PHA and sodium butyrate for 24hr and
placing 1% background fluorescence in the G1b gate. The G1b gate was established based
on PBMC treated with PHA and aphidicolin for 72hr and placing 1% background
fluorescence in the S/G2/M gate. The G0 gate was established based on pure resting
CD4+ T cells (C). (C) The cell cycle stage in unstimulated and pure resting CD4+ T cells
was established based on PHA-stimulated PBMC.
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Figure 4.2. A commonly-used, HIV-based gene therapy vector fails to reverse
transcribe in unstimulated CD4+ T cells.
(A) Diagram of the lentiviral vector genome (HIVvector) used in the experiments
presented in this study. The vector (VRX494) was constructed based on the HIV-1
molecular clone pNL4-3 (24, 25). The vector encodes GFP under the control of the HIV
LTR, a primer-binding site and packaging signal (PBS/&), the central polypurine tract
(cPPT), an anti-sense HIV envelope (AS), and a Rev response element (RRE). The
relative location of the PCR primers and probes used for monitoring DNA intermediates
are indicated by (  ). (B) Unstimulated CD4+ T cells (uCD4T) or (C) an activated
T cell line, CEMss, were spinoculated with pNL4-3 (wtHIV), VRX494
(HIVvector(VSV-G)), or pNL4-3 in the presence of the reverse transcriptase inhibitor
efavirenz (+NNRTI) at a dose equivalent to 1-5 late reverse transcripts per cell, as
estimated in CEMss cells. Late reverse transcription was measured by quantitative PCR
using primers that detect the second strand transfer step of reverse transcription (SST).
Error bars represent the standard deviation of 3 measurements of reverse transcription.




Importantly, the cells were >90% viable at the time points when reverse transcription was
measured (Supplement S4.1), indicating that the lack of infection is not due to cell death.
4.3.2 The viral envelope is the critical factor: VSV-G-pseudotyped virions do not
infect unstimulated CD4+ T cells as assessed by reverse transcription. (Figure 4.3)
One of the major differences between wtHIV and HIVvector(VSV-G) particles, in
addition to the lack of auxiliary proteins, is that the HIV vector is deleted for HIV env
and pseudotyped with VSV-G. We set out to investigate whether this difference was
responsible, at least in part, for the dramatic difference between wtHIV and
HIVvector(VSV-G) reverse transcription in unstimulated cells (Figure 4.2). To do this,
we inoculated unstimulated CD4+ T cells and CD3/CD28 bead-stimulated primary CD4+
T cells with the following four viruses: HIVvector(VSV-G), wtHIV, wtHIV deleted for
env and pseudotyped with VSV-G (HIV"env(VSV-G)), or wtHIV deleted for env and
pseudotyped with X4-tropic HIV Env (HIV"env(HIV Env)). We measured late reverse
transcripts at 0, 24, and 48 hr post-inoculation.
We found that VSV-G envelope is the critical factor that prevented efficient
infection of unstimulated cells. Reverse transcription of HIVvector(VSV-G) or
HIV"env(VSV-G) in unstimulated cells was barely detectable while reverse transcription
of HIV"env(HIV Env) and wtHIV increased over time (Figure 4.3A).  In contrast, all
four viruses reverse transcribed in bead-stimulated primary CD4+ T cells (Figure 4.3B).
The kinetics of reverse transcription in unstimulated cells are not the kinetics of quiescent
or activated cells but rather an intermediate kinetic profile. This likely reflects that
unstimulated cells are in a range of activation states. In addition, we note that other
groups report higher levels of infection of activated cells compared to resting cells (23),
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Figure 4.3. VSV-G-pseudotyped virions have impaired reverse transcription in
unstimulated CD4+ T cells.
(A) Unstimulated CD4+ T cells (uCD4T) or (B) CD3/CD28 bead-stimulated CD4+ T
cells (aCD4T) (28, 29) were spinoculated with HIVvector(VSV-G), pNL4-3 (wtHIV), or
pNL4-3"env pseudotyped with either VSV-G (HIV"env(VSV-G)) or HIV Env
(HIV"env(HIV Env)) at a dose equivalent to ~1 late reverse transcript per cell, as
estimated in CEMss cells. The envelope of the HIV isolate LAI was used to pseudotype
HIV"env particles. Late reverse transcription was measured by quantitative PCR using
primers that detect the second strand transfer step of reverse transcription (SST). The
results were normalized to the peak level of reverse transcription in activated cells (~1
SST/cell). Error bars represent the standard deviation of 3 measurements of reverse
transcription. The figure is representative of 2 experiments. A slight increase in the level
of reverse transcription by HIV"env(VSV-G) was detected by 48hr post-inoculation.
This slight increase in reverse transcription activity could be due to measurement
variation at the lower limit of PCR detection (~0.0001 – 0.005 SST/cell), minimal intra-
virion reverse transcription (30-32), or minimal and delayed reverse transcription. The
apparent variation of background reverse transcription at 0hr post-inoculation among
viruses is likely due to variable contamination of the viral supernatants with plasmid
DNA, which interferes with PCR detection of reverse transcription (Supplement S4.2),
and variable effectiveness of the treatment of the supernatants with DNase. Thus, the
apparent minimal increase of reverse transcription from 0hr post-inoculation by
HIV"env(HIV Env) (Figure 4.3B, dark triangles) is also likely due to contaminating
plasmid DNA in the transfection supernatant.
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than we report. This may be due to variable activation of the cells or due to donor-to-
donor variation. Nevertheless, our findings indicate that HIV particles bearing VSV-G in
place of HIV Env have impaired infection at or before reverse transcription in
unstimulated CD4+ T cells but not in stimulated CD4+ T cells. Thus, the lack of infection
of unstimulated cells by HIVvector(VSV-G) (Figure 4.2B) was due to substituting VSV-
G for X4-tropic HIV Env on the HIVvector particles.
4.3.3 Viral fusion is the critical step: VSV-G-pseudotyped viral particles do not fuse
to unstimulated CD4+ T cells as assessed by the BlaM-Vpr-based fusion assay.
(Figure 4.4)
Since the envelope appeared to be the critical factor, we tested if viral-cell fusion
was the critical step of infection affected by VSV-G. To test this hypothesis, we
employed the BlaM-Vpr virus-to-cell fusion assay (33, 34). In this assay, the dye CCF2, a
%'lactamase substrate that fluoresces green, is added to cells after viral particles that
carry %'lactamase (covalently linked to Vpr (BlaM-Vpr)) have fused. The %'lactamase
then cleaves CCF2, and CCF2 fluorescence changes from green to blue. The extent of
viral fusion can be monitored by flow cytometry as the percentage of cells that convert
from green to blue fluorescence. We prepared BlaM-Vpr-containing wtHIV and
HIV"env(VSV-G) particles, and inoculated unstimulated and stimulated CD4+ T cells.
We found that viral fusion is the critical step of infection affected by VSV-G. We
found that fusion of HIV"env(VSV-G) particles to unstimulated CD4+ T cells was
undetectable (Figure 4.4A), while wtHIV fused efficiently to unstimulated CD4+ T cells
(Figure 4.4B). In contrast, we found that both HIV"env(VSV-G) and wtHIV particles
fused to stimulated CD4+ T cells (Figures 4.4C and D, respectively). We speculate that
high levels of cell activation are required for efficient VSV-G-mediated fusion since
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Figure 4.4. VSV-G pseudotyped virions do not fuse efficiently to unstimulated CD4+
T cells.
(A, B) Unstimulated CD4+ T cells or (C, D) CD3/CD28 bead-stimulated CD4+ T cells
were spinoculated with BlaM-Vpr-containing pNL4-3"env pseudotyped with VSV-G
(HIV"env(VSV-G)) (A, C) or BlaM-Vpr-containing pNL4-3 (wtHIV) (B, D). The viral
inoculums were matched to have an equivalent fusion activity (50% fusion) in CEMss
cells. After spinoculation and induction of fusion at 37°C, the cells were loaded with the
dye CCF2-AM, incubated at 25°C for 12hr, and analyzed by flow cytometry. Gates were
set both by using the corresponding uninfected control and by setting the gate that
measures viral fusion at ~1% background. The figure is representative of 2 experiments.
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VSV-G mediated fusion does not occur with unstimulated cells, which are in a range
from low to intermediate levels of activation (Figure 4.1A, C). Furthermore, we find
VSV-G mediated fusion occurs most efficiently with CEMss cells and with lesser
efficiency with CD3 and CD28 bead-stimulated primary cells. Thus, even though the
viral inoculums are matched for fusion to CEMss cells, HIV Env mediates fusion slightly
more efficiently than VSV-G when we measure fusion to stimulated primary cells.
Nevertheless, these findings indicate that VSV-G can mediate fusion to activated, but not
unstimulated, CD4+ T cells. In addition, our BlaM-Vpr fusion data is consistent with the
very limited amount of early reverse transcription detected over time in unstimulated
cells inoculated with HIVvector(VSV-G) (Supplement S4.3).
4.3.4 VSV-G-pseudotyped virions bind less efficiently to resting CD4+ T cells than
HIV Env pseudotyped virions. (Figure 4.5)
Although, the cellular receptor of VSV-G is still unknown (8, 35), we considered
whether impaired fusion of VSV-G-pseudotyped particles to resting CD4+ T cells could
be due to lack of VSV-G binding. To examine this, we assessed viral binding to resting
and stimulated CD4+ T cells by measuring the level of cell-associated p24 immediately
after inoculation. Pure resting CD4+ T cells (CD25, CD69 and HLA-DR negative cells
(Figure 4.1A)) were spinoculated with HIVvector(VSV-G), or HIVvector(HIV Env).
Following inoculation, the cells were washed to remove unbound virions. The level of
cell-associated p24
Gag
 was measured by ELISA. The number of viral particles bound per
cell was calculated based on the prediction that there are ~15,800 viral particles per
picogram of p24
Gag
 (36). For example, in activated T cells, we found a p24 value for
HIV"env(VSV-G) of 61pg/ml, which translated to 0.005pg/cell and to 78 virions/cell
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(Figure 4.5).
We found that VSV-G-pseudotyped particles bound less efficiently than HIV
Env-pseudotyped particles to resting CD4+ T cells, while both vectors bound to
stimulated cells at similar levels (Figure 4.5). This difference in viral binding to resting
CD4+ T cells between HIVvector(VSV-G) and HIVvector(HIV Env) corresponded to
~7-fold (Figure 4.5). Similar to our current results, we previously demonstrated that
under spinoculation conditions, HIV viral particles bind about ~2-4 fold less to resting
CD4+ T cells than to stimulated cells (37). We attribute this, to differences in the surface
area exposed to viral particles during spinoculation. However, in the case of VSV-G-
mediated binding, we found that particles bound ~21-fold less efficiently to resting cells
compared to stimulated cells. Therefore, the difference in binding to resting cells between
VSV-G and HIV Env is significant and cannot be attributed to differences in surface area
between resting and stimulated cells (Figure 4.5). These results were confirmed by
measuring the level of cell-associated viral RNA after inoculation by reverse
transcriptase PCR (not shown). Based on these observations, we conclude that viral
particles pseudotyped with HIV Env bind better to resting cells than viral particles
pseudotyped with VSV-G. The lower binding may result in slightly lower fusion, but the
reduced binding is unlikely to explain the near complete absence of fusion of VSV-G-
pseudotyped particles to resting CD4+ T cells (Figure 4.4).
4.3.5 HIV Env rescues the ability of the lentiviral vector to transduce resting CD4+
T cells. (Figures 4.6 and 4.7)
Among CD4+ T cells, memory and naïve cells in the G0 stage of the cell cycle
have the longest life span (38, 39). Given that HIVvector(VSV-G) did not efficiently
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Figure 4.5. Binding of VSV-G pseudotyped virions to resting CD4+ T cells is less
than that of wtHIV.
(A) Resting CD4+ T cells (CD25, CD69 and HLA-DR negative) (rCD4T) or CD3/CD28
bead-stimulated CD4+ T cells (aCD4T) were spinoculated with HIVvector(VSV-G) or
HIVvector(HIV Env) at a dose equivalent to ~1 late reverse transcript per cell, as
estimated in CEMss cells. The envelope of the HIV isolate LAI was used to pseudotype
HIVvector particles. Viral binding was determined by measuring the level of cell-
associated viral p24
Gag
 immediately after inoculation. The level of cell-associated p24
Gag
was measured by ELISA. Error bars represent the standard deviation of a combined total
of 6 (resting cells) or 9 (activated cells) measurements of viral binding from 3
inoculations. Asterisks represent statistical significance at p<0.01 as calculated by the
Wilcoxon rank-sum test. The figure is representative of 3 experiments.
118
infect unstimulated CD4+ T cells, while wtHIV does, we decided to test whether
pseudotyping HIVvector particles with X4-tropic HIV Env would allow integration of the
vector into pure G0 resting CD4+ T cells and if this transduction would lead to cellular
activation. To do this, we purified CD25, CD69, and HLA-DR-negative cells from
unstimulated CD4+ T cells (Figure 4.1A, C), and inoculated them with HIVvector(HIV
Env), or HIVvector(VSV-G). We then measured integration using our standard Alu-PCR
assay (21, 40) at 0, 24, 48, and 72 hr post-inoculation. We found that HIVvector(HIV
Env) integrated into both resting and stimulated CD4+ T cells (Figure 4.6A, B), and that
integration occured without significant activation of the cells during and after the
inoculation process (Figure 4.7), confirming our prior findings with wtHIV (27). Cell
activation was assessed by monitoring the level of surface expression of CD25, CD69
and HLA-DR (Figure 4.7A) and by monitoring the level of DNA/RNA staining (11)
(Figure 4.7B) before spinoculation and at 0, 4, and 24 hr post-spinoculation. In contrast to
our findings with HIVvector(HIV Env), we did not detect integration of HIVvector(VSV-
G) to resting CD4+ T cells, but detected integration to activated CD4+ T cells (Figure
4.6A, B). Specifically, the level of transduction by HIVvector(HIV Env) is 100 times
higher than HIVvector(VSV-G) in resting CD4+ T cells, while HIVvector(VSV-G)
integrates ~1000 times  more effectively in stimulated cells compared to resting cells.
Notably this large (~1000 fold) difference in susceptibility between resting and
stimulated did not occur when HIV envelope was used.
For efficient gene therapy, higher levels of transduction than those shown in
Figure 4.6A would be necessary. We therefore tested whether a less diluted virus stock
would yield higher levels of integration (Figure 4.6C). We found that using 5-fold higher
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levels of the same viral stock increased the level of integration in resting CD4+ T cells 5-
fold, such that on average 0.5 proviruses were detected per resting CD4+ T cells, which is
within the range necessary for effective gene therapy. Figure 4.6C is also consistent with
our previous observations with wtHIV that a linear relationship exists between virus
dilution and the level of integration in resting CD4+ T cells (21). We conclude that
pseudotyping HIVvector with HIV Env instead of VSV-G permits transduction of pure
resting CD4+ T cells. Our results suggest that X4-tropic HIV Env is a better gene therapy
envelope than VSV-G when the gene therapy target is resting CD4+ T cells.
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Figure 4.6. Lentiviral vector particles pseudotyped with HIV envelope can
transduce resting CD4+ T cells.
(A) Pure resting CD4+ T cells (rCD4T) (CD25, CD69, HLA-DR negative) or (B)
CD3/CD28 activated CD4+ T cells (aCD4T) were spinoculated with HIVvector(HIV
Env) or HIVvector(VSV-G) at a dose equivalent to ~1 late reverse transcript per cell, as
estimated in stimulated CD4+ T cells. At the indicated time points post inoculation,
integration was measured by Alu-PCR. The graphs represent a combination of 2
experiments. Undetectable levels of integration were plotted directly on the x-axis
without error bars. Error bars represent the standard deviation of 4-5 combined
measurements of integration. (C) Two different dilutions of HIVvector(HIV Env) were
used to inoculate pure resting CD4+ T cells (rCD4T). The envelope of the HIV isolate
LAI was used to pseudotype HIVvector particles. Integration was measured at 48hr post-
infection by Alu-PCR. The graph represents a combination of 2 (1:35 dilution) or 3 (1:7
dilution) experiments. Error bars represent the standard deviation of 5 (1:35 dilution) to




Figure 4.7. Viral particles pseudotyped with HIV envelope do not induce expression
of activation markers or cell cycle entry in resting CD4+ T cells.
(A) Mock-infected or HIVvector(HIV Env)-infected pure resting CD4+ T cells (at ~1-3
SST activity in activated CD4+ T cells) were stained for CD4 and the cell activation
markers CD25, CD69, and HLA-DR at various time points post-inoculation. The gates
for each time point were set using an FMO control corresponding to each time point,
similar to Figure 4.1A. (B) Mock-infected or HIVvector(HIV Env)-infected pure resting
CD4+ T cells (at ~1-3 SST activity in activated CD4+ T cells) were stained with Pyronin
Y and 7AAD to monitor cell cycle progression at 0, 4, and 24hr post-infection. The gates
from Figure 4.1B were applied to establish the cell cycle stage.
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Section 4.4 – Discussion
Here we show that VSV-G envelope does not mediate efficient delivery of an HIV-
based lentiviral vector (HIVvector (VRX494)), to resting CD4+ T cells, in agreement
with a recent report (41). Furthermore, it does not mediate fusion to the endogenous
activated cells among circulating CD4+ T cells. In contrast, wtHIV transduces resting
CD4+ T cells more efficiently. We then dissected this difference between wtHIV and
HIVvector(VSV-G), and determined that HIV envelope is the critical factor, and fusion
the critical step, that determine the susceptibility of unstimulated or pure resting CD4+ T
cells to HIVvector. In other words, VSV-G did not mediate fusion of HIVvector viral
particles to unstimulated or resting CD4+ T cells while HIV envelope did. In agreement
with this, when HIVvector is pseudotyped with HIV envelope instead of VSV-G, the
vector now integrates ~100 times more efficiently into the genomes of resting cells,
without the cells entering into the G1b stage of the cell cycle. Although in the current
study we only tested the ability of an X4-tropic HIV envelope to mediate delivery of a
gene therapy vector into resting CD4+ T cells, we expect that a CCR5-tropic HIV
envelope would also mediate delivery of the vector to resting cells. This possibility is
supported by our recent finding that both CCR5- and CXCR4-tropic HIV can fuse,
reverse transcribe and integrate into resting CD4+ T cells (42). However, in that study,
we found that X4-tropic HIV can efficiently fuse and integrate in both naïve and memory
cells, while CCR5-tropic HIV could not infect naïve cells as efficiently as X4-tropic HIV.
Therefore, the findings reported here suggest that X4-tropic HIV envelope is an attractive
choice for a gene therapy envelope, when the goal is the delivery of a therapeutic gene to
both naïve and memory resting CD4+ T cells.
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Efficient transduction of resting CD4+ T cells is an important goal of gene
transfer strategies. Our approach to understanding the difference between
HIVvector(VSV-G) and wtHIV was to dissect the viral factor(s) and the viral life cycle
step(s) that were involved. The fact that neither HIV"env(VSV-G) nor HIVvector(VSV-
G) infected unstimulated CD4+ T cells, but both wtHIV and HIV"env(HIV Env) did
(Figure 4.3), indicated that HIV Env on the surface of viral particles was the critical viral
factor.  Extending this analysis, we observed that the inability of VSV-G to mediate
transduction of unstimulated and resting CD4+ T cells is mainly due to its inability to
fuse to these cell types (Figure 4.4).  Our results once again emphasize the ability of HIV
to infect resting CD4+ T cells and at the same time emphasize the differences in the
requirements for infection between unstimulated and activated CD4+ T cells.
It is surprising that VSV-G fails to mediate fusion of lentiviral particles to
unstimulated or resting CD4+ T cells because VSV-G is thought to have a nearly
ubiquitous receptor (43). One explanation for why VSV-G fails to fuse to unstimulated
cells is that these cells may not express sufficient levels of the, still unknown, cellular
receptor for VSV-G (8, 35), while it may be expressed sufficiently in stimulated CD4+ T
cells. Consistent with this explanation, we found that VSV-G-pseudotyped particles
bound less efficiently (~7-fold) than HIV Env-carrying particles to resting CD4+ T cells
(Figure 4.5). Nevertheless, reduced binding on its own does not fully account for the
dramatic difference in fusion efficiency of VSV-G to unstimulated and stimulated CD4+
T cells. Even if a lower number of viral particles bound to unstimulated CD4+ T cells,
these particles could have mediated some detectable level of fusion, but did not. Since
VSV-G fuses to cells by a pH-dependent pathway, unlike HIV gp120-mediated fusion,
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another possible explanation for the failure of VSV-G to mediate fusion to unstimulated
CD4+ T cells is that these cells may not have sufficient levels of endocytosis to support
VSV-G-mediated fusion. In fact, it has been shown that the rate of endocytosis in
unstimulated T cells is 10-fold less compared to stimulated T cells, based on the
internalization of the dye FM1-43 (44). Alternatively, if VSV-G-carrying particles are
endocytosed, the endocytic compartment containing the viral particles may not be ideal
for VSV-G-mediated fusion. In cell lines, VSV-G mediates fusion of viral particles in
endocytic compartments beyond the early endosome, such as multivesicular bodies and
late endosomes, but before the endosomes develop into lysosomes (45, 46); although
recent evidence suggests that fusion may also occur in early endosomes (47). Since, it has
been found that early endosomes in unstimulated cells develop into lysosome-like
compartments and not into multivesicular bodies as in stimulated cells (44), VSV-G-
mediated fusion may also be prevented in unstimulated cells by degradation of the
particles in these lysosomal-like compartments. Therefore, it is possible that a
combination of reduced binding, decreased endocytosis and degradation of particles in
lysosomal-like compartments may be largely responsible for the difference in fusion of
VSV-G-pseudotyped particles to unstimulated compared to stimulated CD4+ T cells.
A recent study by Frecha et al., also reported that VSV-G pseudotyped lentiviral
vectors do not transduce resting CD4+ T cells, while lentiviral particles pseudotyped with
measles virus envelope do (41). In that study, transduction was assayed indirectly by
monitoring GFP expression. As this study did not assay the steps of the viral life cycle, it
was unclear why particles pseudotyped with measles virus envelope infected resting cells,
while VSV-G pseudotypes did not. Considering our current work, it appears that measles
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virus envelope also facilitates fusion to resting CD4+ T cells. In addition, it is worth
noting that both measles virus envelope and HIV envelope utilize signaling molecules as
fusion receptors (SLAM and CD46 by measles envelope and CD4 and CCR5/CXCR4 by
HIV). This characteristic of two envelopes that seem to mediate fusion to resting CD4+ T
cells may provide a clue to better understand the resistance of these cells to lentiviral
transduction.
Our previous studies showing that HIV directly transduces resting CD4+ T cells were
initially controversial. Earlier studies had suggested that quiescent CD4+ T cells were
resistant to HIV because of inefficient reverse transcription, nuclear import and
integration (9, 11-16). The discrepancy between our conclusions and those from earlier
studies could be explained by the fact that, in the earlier studies, reverse transcription and
integration were assayed within 24 hours post-inoculation, whereas we performed assays
up to 48-72hrs post inoculation. In support of our conclusion, recent work by Vatakis, et
al. confirmed that HIV integrates into resting CD4+ T cells, but that the pace of infection
is slower than in activated CD4+ T cells (23). In light of our current results, it becomes
clear that the wide use of VSV-G-pseudotyped lentiviral vectors (e.g. HIV"env(VSV-G))
may have also reinforced the misperception that resting CD4+ T cells were completely
resistant to HIV infection. Many of the important studies that describe the requirements
for T cell infection (48, 49) and the role of APOBEC in T cell infection (50, 51) used
VSV-G pseudotyped HIV"env constructs. While these studies provide valuable
information about resting CD4+ T cell biology, the interpretation of these studies may
change given our finding that VSV-G fuses inefficiently to resting CD4+ T cells, while
HIV Env containing viruses fuse, reverse transcribe, and integrate in resting CD4+ T
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cells.
Transducing quiescent cells, such as a quiescent CD4+ T cells, is a major goal of
gene therapy. The observation that HIV envelope can mediate efficient and direct
delivery of lentiviral vectors to resting CD4+ T cells may open new avenues of
development for CD4+ T cell gene therapy. For example, when using lentiviral vectors
pseudotyped with HIV envelope, it will no longer be necessary to activate the cells in
order to transduce them, thus circumventing potentially significant drawbacks of current
protocols. Drawbacks of activating resting CD4+ T cells prior to gene delivery include
that activation may (a) alter the function of the cells, and (b) shorten the half-lives of the
cells, both of which could have unexpected effects on the efficacy of the genetic therapy.
Our finding that HIV envelope mediates delivery of lentiviral vectors to resting CD4+
T cells could be exploited to deliver genes to other cell types that are relatively resistant
to VSV-G mediated delivery. For example, CD4-independent HIV envelopes such as
8XD (52, 53) could be used to deliver vectors to cells that express little or no CD4, such
as G0 hematopoeitic stem cells (54). These cells are desirable targets because cell cycle
entry may reduce the stem cell potential (55, 56). Analogous to resting CD4+ T cells,
stem cells in the G0 stage of the cell cycle appear to be relatively resistant to lentiviral
vector transduction, but can be transduced upon entry to the cell cycle (10). Finally, our
results show that vectors with the native HIV envelope can infect the same cellular
targets as HIV. Thus direct injection of the vector into subjects may become a feasible
gene therapy for HIV infection. Ultimately, our results suggest that more simplified and
direct approaches to transduce resting cells can be developed for efficient gene therapy.
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Section 4.5 – Materials and Methods
4.5.1 Cell lines, plasmids and viruses. The CD4+ T lymphoblastoid cell line CEMss
(57), a subclonal cell line derived from CEM cells (58, 59), was maintained at 1-5(105
cells/ml. The culture medium used to maintain cells was RPMI 1640 (Invitrogen)
supplemented with 10% heat inactivated FBS (Hyclone) and 100ug/ml of penicillin-
streptomycin (Mediatech Inc.). Viral supernatants were prepared by calcium-phosphate
transfection of 293T cells using the following plasmids: pNL4-3 (60), pNL4-
3.HSA.R+.E- (pNL4-3"env) (61, 62), pHIT (VSV-G) (63), a plasmid encoding the HIV
envelope from the isolate LAI (kindly donated by Dr. Robert Doms) and pMM310
(BlaM-vpr) (33). The lentiviral vector VRX494, referred to as HIVvector in this
manuscript, was pseudotyped with either VSV-G or HIV-LAI envelopes and was donated
by VIRxSYS (24).
4.5.2 Purification and stimulation of resting CD4+ T cells. Unstimulated CD4+ T
cells, purified from leukapheresis-enriched PBMC by RosetteSep (StemCell
Technologies) (21), were obtained from the University of Pennsylvania’s Immunology
Core. To obtain pure resting CD4+ T cells, cells were stained with PE-labeled antibodies
against CD25, CD69 and HLA-DR (BD Biosciences) and anti-PE magnetic beads
(Miltenyi Biotec) as recommended by the manufacturers. The labeled cells were then
applied to a magnetic column to separate the cells that expressed activation markers from
the unlabeled resting CD4+ T cells. This method generally yields >98% pure resting
CD4+ T cells (21). In the cases where cells were activated, unpurified CD4+ T cells were
stimulated with CD3/CD28 beads (Invitrogen) at 1 bead per cell for 72hr at 37°C.
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4.5.3 Monitoring cell activation. The level of cell activation was monitored with flow
cytometry before and after infection by measuring the level of activation marker
expression and by measuring the level of DNA/RNA staining using 7AAD and pyronin Y
(11, 26, 64). PBMC (10
6
 cells/ml) stimulated with phytohemagglutinin (PHA) (10µg/ml)
+ IL-2 (10U/ml) were treated with sodium butyrate (2.5mM) (Sigma) or aphidicolin
(10µM) (Sigma) to serve as reference controls to distinguish cells entering the different
stages of the cell cycle.
4.5.4 Inoculations. Resting CD4+ T, stimulated CD4+ T or CEMss cells were
resuspended in viral supernatants at 1(107 cells/ml and spinoculated at 1200(g for 2hr at
25°C (37). After inoculation, the cells were washed twice with PBS + 10% FBS to
remove unbound virions. Following the washing step, cells were cultured at 37°C in
RPMI 1640 supplemented with 10% FBS, 100µg/ml of penicillin-streptomycin and
1.25µM saquinavir (Roche Pharmaceuticals). Selected samples were treated with 1µM of
the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (AIDS Reagents
Program).
4.5.5 Measuring HIV DNA intermediates. At selected time points post-inoculation,
total cellular DNA was purified using the QIAamp DNA Micro Kit (Qiagen). Early
reverse transcription was measured by real-time PCR using primers and a fluorescent
probe that detect the R-U5 region of the HIV LTR (21). Late reverse transcription was
measured by real-time PCR using primers and a fluorescent probe that detect transcripts
that have completed the second-strand transfer (27). Integration was measured by real-
time Alu-PCR as previously described (21) using the primers described by O’Doherty, et
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al. (40). Cell numbers were estimated by measuring the number of %-globin copies per
sample by real-time PCR (37).
4.5.6 Measuring viral fusion. Transfection viral supernatants of pNL4-3 or pNL4-3"env
pseudotyped with VSV-G containing BlaM-Vpr were utilized to inoculate unsimulated
and stimulated CD4+ T cells by spinoculation at 1200(g for 2hr and at 4°C. After
inoculation, the cells were washed twice with cold PBS + 10% FBS to remove unbound
virions. Cells were then resuspended in RPMI + 10% FBS and incubated at 37°C for 30
mins to induce viral fusion. After fusion, cells were washed twice with CO2-independent
medium (Invitrogen) without serum and without antibiotics. A stock CCF2-AM
(Invitrogen) loading solution was prepared for staining the cells: 2µl of CCF2 at
200µg/ml and 8µl of 100 mg/mL Pluronic-F127 surfactant in DMSO and 0.1% acetic
acid, diluted to a total of 1ml with CO2-independent medium without antibiotics or
serum. One million cells were resuspended in 100µl of CCF2 loading solution and
incubated at room temperature for 1hr to allow dye uptake. Cells were subsequently
washed with CO2-independent medium, resuspended in CO2-independent medium
containing 10% FBS and 2.5mM of probenecid (Sigma-Aldrich), and incubated at 25°C
in a CO2-free atmosphere for ~12hr. After incubation, the cells were washed once with
FACS buffer (PBS + 1%BSA + 2mM EDTA) and fixed with 1% paraformaldehyde.
Fixed cells were then analyzed by flow cytometry using a BD™ LSR II flow cytometer.
4.5.7 Measuring viral binding. Viral binding was assessed by measuring the level of
cell-associated p24
Gag
 in samples collected immediately after inoculation using a p24-
specific ELISA (Perkin Elmer). The approximate number of viral particles bound to cells
was calculated as previously described (37).
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Chapter 5 – Conclusions
Section 5.1 – Summary of Results
Understanding how the latent reservoir found in resting CD4+ T cells forms is an
aspect of HIV pathogenesis with potential implications for the development of more
effective treatment strategies to control the infection. Our laboratory provided evidence
that post-integration latency can form by direct integration of the HIV genome into
resting CD4+ T cells (1). This initial study was received with some skepticism due to the
methods employed for evaluating the susceptibility of resting cells. More specifically, we
used spinoculation to improve the viral binding to the target cells in order to increase the
signals from HIV DNA intermediates. The use of this method raised the possibility of
rendering resting cells susceptible to HIV infection artificially. This dissertation followed
up on the original finding that HIV can integrate directly into resting cells and addressed
some of the concerns that arose from the original study. To address the possibility that
spinoculation could artificially increase the susceptibility of resting cells to HIV
integration, we conducted experiments with or without spinoculation of viral particles
onto resting cells (Chapter 2). We found that HIV could still integrate directly into resting
cells regardless of the method used for inoculation. Furthermore, the level of integration
detected in resting cells was proportionally related to the inoculum. In other words, the
level of integration detected was dose dependent regardless of the inoculation protocol;
thus, the size of the inoculum did not appear to improve the susceptibility of the cells to
infection. To detect integration when the virus was delivered at very low inoculums, we
improved the sensitivity of an Alu-PCR-based method for detecting HIV integration. This
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method incorporated a polyclonal integration standard that carries one HIV integration
event per cell and captures the diversity of HIV integration sites. In addition, this assay
incorporates repetitive sampling and thus the sensitivity is limited only by the number of
measurement repeats that the user is willing to conduct. These modifications improved
the sensitivity of the assay, allowing the detection of 1 integration event per 10,000 cells
when integration is measured 40 times.
Another question raised from our work was the possibility that our inoculations
targeted specific subsets among the resting cell population, such as cells with low levels
of cellular activation and memory cells. These subsets could have potentially been more
permissive to HIV integration and could have represented the majority of the infected
cells detected by PCR. We addressed these possibilities by comparing the susceptibility
of pure resting cells, based on activation marker expression, to cells that express
intermediate levels of these markers (Chapter 2). We found that both populations of cells
had similar susceptibility to HIV integration. We also compared the efficiency of each
early step in the viral life cycle between resting memory and resting naïve cells (Chapter
3). All the early steps of the viral life cycle (binding, fusion, reverse transcription and
integration) took place in both memory and naïve cells. This process took place without
the help from endogenous dendritic cells or the addition of deoxynucleosides. However,
infection of naïve cells was envelope tropism-dependent. While X4-tropic HIV (pNL4-3
and IIIB) was able to integrate into both memory and naïve cells, R5-tropic HIV (BaL,
RF-1, pNL-AD8) was not able to integrate efficiently in naïve cells due to inefficient
viral fusion.
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Since our evidence supports the ability of HIV to directly integrate into resting
cells, we explored the possibility of applying this knowledge to gene therapy (Chapter 4).
Lentiviral vectors are commonly used for the delivery of genes of interest directly to cells
in gene therapy research. However, resting CD4+ T cells have been difficult to transduce
with lentiviral vectors. We found that the difficulty in transducing these cells was partly
due to the use of VSV-G for pseudotyping lentiviral vectors, since this virus is unable to
mediate efficient fusion of lentiviral particles to resting cells. If this envelope is replaced
with the native HIV envelope, the lentiviral vector is now able to fuse, reverse transcribe
and integrate in resting cells.
Altogether, the work described in this dissertation provides insight into the
biology of HIV and provides potential applications of this knowledge for the treatment
and prevention of HIV infection.
Section 5.2 – Direct HIV infection of resting CD4+ T cells: a new paradigm in HIV
latency
The most widely accepted model for the establishment of the latent reservoir in
resting CD4+ T cells suggests that HIV integrates into these cells during the transition
from an activated to a resting state. However, this theory is inconsistent with some
observations from in vivo studies. First, significant infection of apparently resting cells
(CD69, CD25 or KI-67-negative cells) is seen during acute SIV infection of rhesus
macaques (2). Second, infection of naïve cells, a more quiescent cell subset, has been
detected in HIV-infected individuals (3-6). Therefore, a model for the formation of the
latent reservoir that accounts for these observations in vivo is required.
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The evidence presented in this dissertation indicates that an activation step is not
required for the establishment of post-integration latency in resting cells. Unlike earlier
work, we found that neither reverse transcription nor integration appear to be blocked in
resting cells. We also found that this process can take place even when the viral inoculum
is very low (MOI = ~0.0025, Figure 2.5). However, pure resting cells are not always a
majority of the total CD4+ T cell numbers in the blood (compare Figure 2.3 to Figure
2.6) and commonly, cells with intermediate levels of activation marker expression are
significantly present. Given that CD4+ T cells live in nutrient and cytokine-rich
environments, such as the blood and lymphoid tissue, it is not surprising that CD4+ T
cells exist in a range of cell activation levels. Cells with intermediate levels of cell
activation represent the major contaminant in our experiments and infection of these cells
could have potentially accounted for most of the integration detected among resting cells.
Yet, these cells appear to be equally susceptible to HIV integration as pure resting CD4+
T cells. Our works suggests that cells at the different levels of activation, from the most
resting (based on both activation markers and cell cycle staining, see Figures 2.3, 2.6, 4.1,
4.7) to the most activated, are susceptible to HIV integration. Finally, this dissertation has
also provided evidence that cell differentiation does not dictate susceptibility to HIV
integration, as both resting memory and resting naïve CD4+ T cells are susceptible to
HIV integration. Rather, other factors, such as receptor availability, influence
susceptibility to HIV.
The evidence provided here, together with the finding that both viral protein
production (1, 7) and infectious virus production (Mexas, et al., manuscript in
preparation) are detected from stimulated resting cells, strongly favors a model of post-
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integration latency forming directly in resting cells, where HIV can directly integrate into
resting CD4+ T cells and the integrated virus can be stimulated to produce new viral
particles upon cellular activation. In addition, since the total levels of integration depend
on the inoculum and the levels of integration approach those seen in activated cells (1-10-
fold higher than in resting cells), suggests direct infection of resting cells may occur in
vivo at a higher frequency than has been recognized. The probability of resting cells
becoming directly infected in vivo would only increase if the nutrient and cytokine-rich
environment in tissues is considered as a factor favoring infection of these cells (4).
Based on our in vitro experiments, we estimate that approximately 20% late reverse
transcripts (SST) integrate in resting cells (Figures 2.7 and 3.8), though we find that it
ranges between 10% to 50% (unpublished work). These ratios, combined with the finding
that the majority of the infected cells during acute infection appear to be resting (2, 8),
strongly supports the hypothesis that the latent reservoir can also form in part by direct
infection of resting cells.
Several reasons could account for why direct infection of resting cells has not
been properly acknowledged. First, prior work that investigated the susceptibility of
resting cells to HIV infection focused on early time points post-infection (before 24hr),
whereas we find that integration peaks around 48hr post-infection (Figure 4.6 and (7)).
Second, viral inoculum and detection sensitivity of HIV DNA intermediates could have
affected the accuracy of the estimates. Given that activated cells are capable of infectious
virus production, and resting cells are not, HIV DNA intermediate signals from weaker
inoculums can be more easily amplified under conditions of spreading infection. This
amplification brings the signals of DNA intermediates within the reach of less sensitive
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PCR-based assays. With the use of spinoculation and nested kinetic Alu-PCR, we are able
to amplify the signals from HIV DNA intermediates even when the infectivity of the
virus stock is weak. Finally, the wide use of VSV-G-pseudotyped lentiviral vectors has
continued to support the notion that resting cells are resistant to HIV infection (9, 10). As
explained in Chapter 4, VSV-G is unable to deliver HIV, or lentiviral vectors, to resting
cells because it is unable to mediate efficient fusion of the viral particles to the target
cells. On the other hand, if the viral particles are pseudotyped with the native HIV
envelope, this block is rescued. Nevertheless, although HIV can integrate directly into
resting cells, it appears that infection of these cells differs from infection of activated
cells, and further study comparing infection of resting cells to activated cells is necessary.
Section 5.3 – Requirements for HIV infection of resting cells
The work presented in this dissertation suggests that resting cells are susceptible
to HIV integration. However, it also provides evidence that infection of resting cells is
not identical to infection of fully activated cells. The first difference that can be noted is
the pace of the infection in resting cells. It was originally hypothesized that this delay in
the infection kinetics, specifically reverse transcription, was due to lower
deoxynucleoside pools (11). However, work by Plesa, et al. (7) suggests that lower
nucleoside pools do not seem to fully account for the difference in the infection kinetics
and total levels of integration between resting and activated cells. Specifically,
supplementing resting cells with deoxynucleosides during infection did not revert the
infection kinetics to the kinetics seen in activated cells. This suggests that additional
factors may be involved in HIV infection of CD4+ T cells.
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Two cellular factor families have been implicated in providing resistance against
HIV infection: the TRIM and APOBEC family of proteins. The best understood member
of the TRIM family is TRIM5!, which is responsible for providing resistance against
cross-species infection with HIV (12-19). Although this factor appears to be ineffective
against HIV infection in humans, it was possible that this or a factor with similar
properties, that affected the delivery of the pre-integration complex to the cell nucleus,
was responsible for the delayed kinetics in resting cells. One characteristic of TRIM5!,
and a potentially similar cellular factor, is its saturability. In other words, if enough viral
particles are delivered to the cells, TRIM5! becomes saturated and can no longer block
infection by the additional viruses. A saturation effect would be detected as a non-dose
dependent change in the levels of HIV DNA intermediates and a threshold viral dose
required for the detection of these intermediates. However, our work did not show a
saturation effect regardless of the inoculation method, suggesting that a factor with
similar properties as TRIM5! is not responsible for resistance of resting cells to HIV
(Chapter 2). Conversely, infection seems to be dose dependent, from very low inoculum
(at ~0.0005 proviruses/cell in Figure 2.4) to high inoculum (2 proviruses/cell in
Supplement S2.2).
The best understood member of the APOBEC family of proteins is APOBEC3G.
This factor was originally associated with resistance to replicating HIV with defective vif
(20). It was found that HIV defective for vif could not replicate in primary cells because
the cellular protein APOBEC3G is incorporated into newly made viral particles and
causes significant G-to-A mutations in the viral genome, thus severely attenuating its
infectivity. However, more recent work by Chiu, et al. suggested that, in addition to this
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function, APOBEC3G could also restrict infection of HIV in resting cells by affecting
reverse transcription of the incoming particle (21). APOBEC3G exists in a high
molecular mass form in activated cells (21) composed of RNA complexes, including
RNA from retro-elements such as Alu (22), while it remains in a low molecular mass
configuration in resting cells. Since the low molecular form of APOBEC is enzymatically
active, it is therefore possible that it could contribute to slow the kinetics of HIV infection
in resting cells and could reduce the total number of integration events, but still not fully
block infection. Unfortunately, the studies that have addressed the role of APOBEC3G in
infection of resting cells used lentiviral particles deleted for HIV envelope and
pseudotyped with VSV-G (10, 21, 23). Since VSV-G cannot mediate fusion of lentiviral
particles to resting cells, it remains unclear to what extent APOBEC3G affects incoming
virions.
So far, the only factor that appears to significantly influence the susceptibility of
resting cells to HIV infection is receptor availability. As shown in Chapter 3, both resting
memory and resting naïve CD4+ T cells are susceptible to HIV infection. The differences
between these two cell subsets can be grouped into 3 characteristics that may be relevant
to HIV infection: a) cell differentiation, b) resting state, and c) co-receptor expression. Of
the two cell subsets, naïve cells are considered the most resistant to HIV infection. This
resistance could partly be attributed to their differentiation, since naïve cells have yet to
encounter antigen and become stimulated to perform their immunological functions.
Also, naïve cells appear to be in a more quiescent state relative to memory cells based on
the level of RNA expression (24). Despite these characteristics of naïve cells, we found
that naïve cells are permissive to HIV infection as long as the virus has the appropriate
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co-receptor tropism. While CXCR4-tropic HIV was able to bind, fuse, reverse transcribe
and finally integrate into resting naïve cells, CCR5-tropic HIV fused inefficiently to these
cells. This is consistent with relative co-receptor expression. While memory cells express
both CCR5 and CXCR4 (Figure 3.2), naïve cells express mostly CXCR4 and little CCR5.
These findings suggest that neither differentiation nor the level of quiescence
significantly affect HIV infection. Instead, it appears that receptor availability is the main
limiting factor for infection of resting cells.
This hypothesis is supported by evidence from experiments conducted with
lentiviral vectors pseudotyped with VSV-G. The cellular entry receptor for this viral
envelope has long been suspected to be the cellular lipid phophatidylserine (25), giving
VSV-G a nearly universal cell tropism. However, later work suggests that this may not be
the receptor for VSV-G mediated viral entry (26); thus, the cellular entry receptor for
VSV-G remains to be identified. Nevertheless, this viral envelope has the ability to bind
but not to mediate fusion of lentiviral particles to resting CD4+ T cells (Figures 4.4 and
4.5). This finding was later confirmed by another study (27). Conversely, if viral particles
are pseudotyped with HIV envelope, the ability to fuse, reverse transcribe and integrate
into resting cells is restored. Therefore, in an extension to the hypothesis that receptor
availability is the limiting step influencing HIV infection of resting cells, it appears that if
the viral particle carries the proper envelope to mediate fusion, the incoming virion will
reverse transcribe and integrate into resting cells.
The finding that VSV-G does not mediate fusion to resting cells may appear to
contradict some of the findings presented in Chapters 2 and 3, where viral particles
pseudotyped with VSV-G were shown to reverse transcribe and integrate into resting
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cells. However, the viruses used in those experiments were prepared by transfection of
293T with plasmids encoding full length HIV and VSV-G. These transfections appear to
result in particles that carry both VSV-G and HIV gp120, which are capable of fusing to
resting cells (unpublished work). Ongoing work in our laboratory is aimed at elucidating
the mechanism that these particles utilize to mediate fusion to resting cells.
In addition to gp120 and the gag-pol protein products, wild type HIV carries the
auxiliary proteins Vif, Nef, and Vpr (28-32). These proteins have been suggested to aid
during reverse transcription and nuclear import of the incoming virion and its pre-
integration complex (33-35). However, the evidence gathered from the experiments
conducted with the lentiviral vector (Chapter 4), which lack all of these auxiliary
proteins, and work done with individual mutations of each auxiliary protein (unpublished
data) suggests that the incorporation of the auxiliary proteins into virions is not essential
for integration into resting CD4+ T cells. This is in agreement with published work that
addresses the importance of intravirion auxiliary proteins (36, 37). However, more
detailed work is required to understand the importance of intavirion auxiliary proteins
during infection of resting cells.
The lentiviral vector used for the studies described in Chapter 4, VRX494, is
based on the viral clone pNL4-3. To make this virus suitable and safe for gene therapy
studies, all the natural HIV genes were significantly truncated to prevent viral protein
production after integration of the vector into the cells. The only features that were
retained from pNL4-3 are those essential for particle assembly during transfection (long
terminal repeats, Rev response element and psi packaging signal), reverse transcription
(central polypurine tract, 3’ polypurine tracts and primer binding site), and expression of
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the therapeutic gene (long terminal repeat). Given that the vector is able to integrate into
resting cells, it appears that no additional features in the HIV genome are required for
integration into resting cells.
Altogether, the work presented in this dissertation suggests that the only barriers
to HIV infection in resting cells are viral fusion (influenced by viral envelope tropism and
cellular receptor availability) and infection kinetics (potentially influenced by a cellular
factor).
Section 5.4 – Applying knowledge from HIV infection of resting CD4+ T cells
The finding that HIV can directly infect resting CD4+ T cells without cellular
stimulation opens new avenues for the study of HIV pathogenesis and potential
applications that could be influential in the treatment of HIV infection. Despite the
evidence indicating that HIV can infect resting cells directly, some differences in
susceptibility between resting and stimulated cells still remain. The HIV infection
kinetics in resting cells are slower than in activated cells and often, the total levels of
integration in resting cells approach but do not reach the levels seen in activated cells.
These differences do not appear to be fully attributable to deoxynucleoside levels; instead
it appears that cellular factors, such as APOBEC, may be negatively influencing the
progression of the early steps of infection in resting cells. Alternatively, it is also possible
that factors that may be present in activated cells may be increasing the rate of infection.
Further study on what factors, or conditions, affect the progression of HIV infection in
resting cells relative to activated cells could reveal the existence of factors that could be
manipulated to weaken the progression of HIV infection in CD4+ T cells. In addition,
given that resting cells serve as a major reservoir for the virus in vivo, understanding the
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requirements for establishing latency in resting cells could influence the development of
future therapeutic strategies to decrease, eliminate or prevent the establishment of this
reservoir.
The finding that HIV can integrate directly into resting cells also opens the doors
for the development of more effective gene therapeutic strategies against HIV and other
CD4+ T cell disorders. Direct gene delivery to resting cells avoids artificial manipulation
of the cells, which could potentially affect the normal life span and behavior of the cells.
An additional advantage of delivering genes to resting cells directly is that HIV appears
to favor integration into gene dense regions less than in activated cells (38). This may
further reduce the probability of the therapeutic gene interfering with normal host gene
expression and normal cell behavior.
Since HIV infection of resting cells seems to differ from infection of activated
cells, the biology of HIV infection in activated cells is not representative of infection of
resting cells. For example, although integration takes place in both resting and activated
cells, there is a significant difference in the ability of resting cells to produce viral
proteins and infectious viral particles. Thus, the differences are not simple and required
further study. In other words, the evidence presented here, though it indicates that resting
cells are susceptible to HIV infection, also highlights that resting CD4+ T cells should be
studied as separate targets of HIV independent from activated cells. Furthermore,
heterogeneous HIV infection seems to occur among resting cells. We have found that a
percentage of resting cells infected in vitro are capable of viral protein production
without cell stimulation and without infectious particle production, while the remainder
of cells do not (unpublished work). This suggests that latency may exist in different
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forms. Further work on the biology of HIV infection of resting CD4+ T cells may yet
reveal new aspects of HIV infection critical for understanding HIV pathogenesis in vivo.
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Supplement S2.1. Generation of an integration standard (IS) cell line.
To calculate HIV integration events, we needed to compare the level of integration in our
unknown samples to a standard. The standard needed to contain diverse integration sites
to accurately reflect integration in vivo (26). To generate a standard with diverse
integration sites, we used the strategy outlined in Supplement S2.1. pNL4-
3"env/EGFP/HygR (Supplement S2.1A) and pVSVG, an expression plasmid for
vesicular stomatitis virus glycoprotein (VSV-G), were co-transfected into 293T cells to
generate pseudotyped virions bearing the HIV"env genome and VSV-G glycoprotein.
CEMss T cells (or 293 cells) were inoculated by spinoculation with transfection
supernatant containing pseudotyped virions. The pseudotyped virions lacked HIV env, so
infection was limited to a single cycle, and contained the coding sequence of EGFP and
hygromycin resistance in place of the nef gene. The infected cells were grown for 28 days
under hygromycin selection and sorted for EGFP expression. Soon after infection, both
integrated and unintegrated DNA were detectable; however after 28 days only integrated
DNA was detectable by Southern blot (not shown but previously described (130)). We
then measured the level of HIV DNA/cell in this Integration Standard (IS) cell line using
kinetic PCR (171) and detected ~1 copy/cell (Supplement S2.1B). Given that all of the
DNA was integrated, we thus concluded that there is ~1 integration event per cell present
in the IS cell line. We then used the same DNA in our two-step PCR assay to detect
integration and generate a standard curve by plotting the number of proviruses vs the
cycle threshold. In the first step of the PCR assay, we amplified DNA using either Alu
and gag primers or only the gag primer (see the PCR conditions section of Materials and
methods for explanation). In the second step of the PCR assay, we used HIV-1 specific
primers, which detect Alu-gag and gag-only amplicons, but do not detect Alu-Alu
amplicons.
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Supplement S2.2. Integration of HIV-1 in CD4
+
 T cells after spinoculation also
exhibits a dose dependent decrease in integration with each dilution.
ppCD4
+
 T cells were inoculated with three-fold dilutions of supernatant containing VSV-
G pseudotyped pNL4-3. Cells were inoculated by spinoculation for 2hr at 25°C, then
washed and the level of cell associated virus (viral binding) was determined at the most
concentrated and most dilute doses by p24 ELISA. The cells were cultured for 3 days,
DNA was prepared, and reverse transcription and integration were measured. Similar to
Figure 2.4, a dose-dependent decrease in integration and RU5 reverse transcripts was
observed with serial dilution of the viral inoculum. The results are presented in provirus
per cell (A), log (3) of provirus per cell (B), RU5 per cell (C) and log(3) RU5 per cell
(D). AZT inhibited reverse transcription (78%) and integration (99%) (added at the top
dose). Error bars represent the standard deviation of 16 measurements of integration and
2-4 measurements of reverse transcripts, for each virus dilution depending on sample
availability. The number of proviruses/cell and RU5/cell are written above each point (B,
D).
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Supplement S3.1. Viral fusion to resting CD4+ T cells in the presence of the fusion
inhibitor enfurvitide cannot be detected by the BlaM-Vpr assay.
Resting CD4+ T cells were spinoculated with X4-HIV (pNL4-3) particles containing
BlaM-Vpr in the presence or absence of 10ug/ml of the fusion inhibitor enfurvitide (T-
20). The gate that measures the level of fusion was set based on a sample infected with
X4-HIV that did not contain BlaM-Vpr and a background signal of 0.5%.
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Supplement S4.1. Unstimulated CD4+ T cells are viable and a minimal number of
viable cells are lost after spinoculation with HIVvector(VSV-G).
Viability and numbers of unstimulated CD4+ T cells were assessed at 0, 24, and 48hr
post-inoculation with the trypan blue cell viability dye. Percent cell recovery was
calculated as the percent of viable cells recovered from the cell input at time 0hr. Cell
samples were diluted 1:10 in trypan blue and cells were counted using a hemacytometer.
Percent cell recovery is representative of the average of 2 cell counts.
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Supplement S4.2. Plasmid DNA is responsible in large part for the reverse
transcription signal obtained at 0hr post-inoculation.
Unstimulated CD4+ T cells were spinoculated with pNL4-3 transfection supernatant in
the presence or absence of the reverse transcription inhibitor efavirenz (NNRTI). Late
reverse transcription was measured at the indicated time points by quantitative PCR using
primers that detect the second strand transfer step of reverse transcription (SST). Error
bars represent the standard deviation of 3 measurements of reverse transcription.
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Supplement S4.3. Early reverse transcription, like late reverse transcription, is not
detected in unstimulated CD4+ T cells inoculated with HIVvector(VSV-G).
(A) Unstimulated CD4+ T cells (uCD4T) or (B) an activated T cell line, CEMss, were
spinoculated with pNL4-3 (wtHIV), VRX494 (HIVvector(VSV-G)), or pNL4-3 in the
presence of the reverse transcriptase inhibitor efavirenz (+NNRTI). Early reverse
transcription was measured by quantitative PCR using primers that recognize the R-U5
region of the HIV-LTR. Error bars represent the standard deviation of 3 measurements of
reverse transcription. The figure is representative of 3 experiments.
